Bayesian Pathway Analysis in Epigenetics by Wright, Alan
This copy of the thesis has been supplied on condition that anyone who consults it is
understood to recognize that its copyright rests with its author and that no quotation from
the thesis and no information derived from it may be published without the author’s prior
consent.

Bayesian Pathway analysis in Epigenetics
by
Alan Wright
A thesis submitted to Plymouth University in partial fulfillment of the
requirements for the degree of
DOCTOR OF PHILOSOPHY
School of Computing and Mathematics
Faculty of Science and Technology
Plymouth University
November 2012

Alan Wright
Bayesian Pathway analysis in Epigenetics
Abstract
A typical gene expression data set consists of measurements of a large number of gene
expressions, on a relatively small number of subjects, classified according to two or more
outcomes, for example cancer or non-cancer. The identification of associations between
gene expressions and outcome is a huge multiple testing problem. Early approaches to
this problem involved the application of thousands of univariate tests with corrections for
multiplicity.
Over the past decade, numerous studies have demonstrated that analyzing gene ex-
pression data structured into predefined gene sets can produce benefits in terms of statis-
tical power and robustness when compared to alternative approaches. This thesis presents
the results of research on gene set analysis. In particular, it examines the properties of
some existing methods for the analysis of gene sets. It introduces novel Bayesian meth-
ods for gene set analysis. A distinguishing feature of these methods is that the model is
specified conditionally on the expression data, whereas other methods of gene set analysis
and IGA generally make inferences conditionally on the outcome.
Computer simulation is used to compare three common established methods for gene
set analysis. In this simulation study a new procedure for the simulation of gene expres-
sion data is introduced. The simulation studies are used to identify situations in which the
established methods perform poorly.
The Bayesian approaches developed in this thesis apply reversible jump Markov chain
Monte Carlo (RJMCMC) techniques to model gene expression effects on phenotype. The
reversible jump step in the modelling procedure allows for posterior probabilities for ac-
tiveness of gene set to be produced. These mixture models reverse the generally accepted
conditionality and model outcome given gene expression, which is a more intuitive as-
sumption when modelling the pathway to phenotype. It is demonstrated that the two
models proposed may be superior to the established methods studied.
v
There is considerable scope for further development of this line of research, which is
appealing in terms of the use of mixture model priors that reflect the belief that a relatively
small number of genes, restricted to a small number of gene sets, are associated with the
outcome.
vi
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Chapter 1
Introduction
1.1 Overview
Epigenetics is the study of epigenetic inheritance, which is a set of reversible heritable
changes in gene function or phenotype that occur without a change in DNA sequence.
These changes can be induced spontaneously, in response to environmental factors, or
in response to the presence of a particular allele, even if it is absent from subsequent
generations. Epigenetics includes the study of effects that are inherited from one cell
generation to the next, whether these occur in embryonic morphogenesis, regeneration,
normal turnover of cells, tumors, or the replication of single celled organisms. Although
there are many mechanisms and processes that come under the title of epigenetics, this
thesis concentrates on the area of gene expression.
Projects in the area of gene expression are often referred to as Gene expression stud-
ies and generally attempt to link genetic contributors, along with certain suitable demo-
graphic, environmental and lifestyle information, to disease or phenotype.
The term gene expression describes the level of protein production from genes and is
quantified by measuring the relative abundance of either protein or ribonucleic acid (RNA)
from biological samples. The expression of genes is determined by many factors, both
internal (inside the cell) and external (from both other cells and the outside environment)
and so expression data is useful when modelling and predicting the occurrence or presence
of disease in the here and now, rather than simply saying that a subjects genetic code
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suggests that at some point they could be susceptible to some disease. In analyzing genetic
data it is necessary to have a reasonable understanding of the processes within the cell
that result in such data. To this end the following section proceeds to give an introduction
to the underlying biological processes behind gene expression and discusses how gene
expression is measured and quantified.
1.2 DNA, the gene and gene expression
The human anatomy can be organized into many specific organs and tissues, all of which
perform certain roles in the growth, repair and functioning of the body. All organs and
tissues are made up of millions of cells, with groups of cells working in concert to a
common task. Due to this, the cell is often referred to as the building block of life. Figure
1.1 shows the generalized structure of a cell.
(1) nucleolus
(2) nucleus
(3) ribosome
(4) vesicle
(5) rough endoplasmic reticulum (ER)
(6) Golgi apparatus
(7) Cytoskeleton
(8) smooth endoplasmic reticulum
(9) mitochondria
(10) vacuole
(11) cytoplasm
(12) lysosome
(13) centrioles within centrosome
Figure 1.1: Simplified structure of a cell
The nucleus((2)) contains the cells chromosomes, which are made up of deoxyri-
bonucleic acid (DNA), and is where the majority of DNA replication and ribonucleic acid
(RNA) synthesis occurs.
DNA is a nucleic acid that contains the information used in the growth and repair of all
living organisms. Eukaryotic organisms store most of their DNA inside the cell nucleus
and some of their DNA in organelles. The main role of DNA is to store information and
is often compared to a set of blueprints, as it carries the information needed to construct
ribonucleic acid (RNA) and hence proteins. The DNA segments that carry this genetic
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information are called genes. Other DNA sequences have structural purposes, or are
involved in regulating the use of this genetic information.
DNA is helical in structure and is constructed of two long polymers of units called
nucleotides, with backbones made of sugars and phosphate groups joined by ester bonds.
These two strands run anti-parallel of one another. Attached to each sugar is one of four
molecules, these are Adenine (A), Cytosine (C), Guanine (G) and Thymine (T). These
molecules are known as bases. Of these bases only A can bond to T and C to G, thus
constraining the two stands to run anti-parallel of one another. It is the sequence of these
four bases along the backbone that encodes information for the construction of RNA and
hence proteins. Figure 1.2 shows a simplified segment of unravelled DNA.
A
T
C
G C
G
A A
TT
G
C
T
A
C
G
A
T
Sugar Phosphate
Backbone
Sugar Phosphate
Backbone
5’
3’
3’
5’
Figure 1.2: Simplified structure of DNA
RNA is a single strand of nucleotides and can be visualized as if it were one strand of
the DNA double helix. The main differences between RNA and DNA are
• RNA is generally single stranded, whereas DNA is generally double stranded.
• DNA has a Deoxyribose sugar backbone, whereas RNA has a Ribose sugar back-
bone. As the name suggests, deoxyribose is the sugar ribose minus an oxygen atom.
• When RNA is transcribed from DNA, the base Thymine is replaced by the base
Uracil (U).
There are several distinct types of RNA some of which will be outlined when required in
the text to come.
A gene is a section of DNA that codes for RNA chains and hence proteins, which in
turn control all processes within the cell. Genes describe and control the heredity in all
3
living organisms and specific genes code for certain phenotypes, for example, there is a
gene for eye colour and each variant of that gene is called an allele.
1.2.1 Transcription
Inside the cells nucleus some genes are active almost constantly, but others have to be
turned on or off to cater for the needs of the cell or organism. Genes which are turned on
or off need some signal to activate/ deactivate them. This is generally facilitated by either
a signal from within the cell, for example from a regulatory gene whose job is to turn
other genes on or off, or from a signal outside of the cell, for example some hormone. A
gene is known as active when the process of transcription is carried out.
Transcription describes the process by which a DNA nucleotide sequence is tran-
scribed into an RNA nucleotide sequence. The DNA sequence is copied by the enzyme
RNA polymerase to produce a complimentary nucleotide RNA strand, called messenger
RNA (mRNA), which then goes on to carry the genetic message to the protein synthe-
sizing part of the cell. The stretch of DNA transcribed into an RNA molecule is called a
transcription unit. A transcription unit that is complimentarily copied into RNA contains
sequences which direct and regulate protein synthesis in addition to the coding sequence
that is translated into protein itself. There is only one strand of DNA that is transcribed
and it is called the template strand. The template strand provides the template for order-
ing the sequence of complimentary nucleotides in an RNA transcript. The other strand
is known as the coding strand and is very similar to the created RNA strand with Uracil
being substituted in place of Thymine. Transcription can be split into five stages; pre-
initiation, initiation, promoter clearance, elongation and termination.
• Pre-initiation - RNA polymerase binds to the DNA and along with other enzymes it
unravels a section of the DNA to create an initiation bubble. This enables the RNA
polymerase access to the template strand of the given transcription unit.
• Initiation - The binding of RNA polymerase and hence the initiation of transcription
is mediated by a collection of proteins called transcription factors. Only after certain
transcription factors are attached to the promoter does the RNA polymerase bind to
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Figure 1.3: Simplified transcription initiation (RNA-P∼RNA polymerase)
it, forming a transcription initiation complex. This can be seen pictorially in Figure
1.3.
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Figure 1.4: Simplified transcription elongation (RNA-P∼RNA polymerase)
• Promoter clearance - The RNA polymerase begins to move along the template
strand, bonding bases to form the RNA strand. During the time after the first bond
is synthesized, when the RNA polymerize must clear the promoter, it is common for
the RNA transcript to be released, thus producing a truncated transcript. This occur-
rence is known as abortive initiation. Once the transcript is around 23 nucleotides
long abortive initiation tends not to occur, and so Elongation can begin.
• Elongation - As transcription proceeds, RNA polymerase travels along the template
strand and produces the complementary base to that on the template strand in order
to create the complimentary strand of RNA. This is shown in Figure 1.4. RNA
polymerase traverses the template strand from 3’ to 5’, however the coding strand
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is generally used as reference (as other than U being substituted for T it is very
similar) so transcription is said to go from 5’ to 3’.
• Termination - Transcription termination in Eukaryotes is not well understood. It
involves the cleavage of the new RNA transcript, followed by addition of A’s at the
3’ end by the process of polyadenylation, for which no template is needed. Figure
1.5 illustrates this.
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Figure 1.5: Simplified transcription termination (RNA-P∼RNA polymerase)
From this process a section of RNA that will code for a specific protein is produced.
1.2.2 Translation
Translation describes the ‘translation’ of RNA into protein. Before defining this process
in detail it is useful to differentiate between the types of RNA involved in Translation:
• Messenger RNA (mRNA)- carries the information for the coding of a protein from
the DNA to the ribosome. mRNA is formed by the process of Transcription, which
is outlined above;
• Transfer RNA (tRNA)- Is a relatively small RNA molecule. Each tRNA molecule
carries one specific amino acid, which it carries to the ribosome. tRNA contains a
three base region called the anticodon that can base pair to a complimentary three
base codon region on mRNA. Each type of tRNA molecule can be attached to only
one type of amino acid and this is how different proteins are specified. tRNA is
never translated into protein;
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• Ribosomal RNA (rRNA)- There are several types of rRNA, and along with certain
specific proteins they form a ribosome. As with tRNA, rRNA is never translated
into protein.
Ribosomes are the components of cells that construct proteins. They are found in the
cells cytoplasm and they use amino acids, tRNA and mRNA to produce proteins. Amino
acids can be thought of here as the building block of proteins; they are molecules all that
contain a certain group of elements and what is known as a side chain, they differ by what
this side chain is constructed of.
C A A G U C A U G C A A G U C A
A C GA G U
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Acid
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Amino
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Amino
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Acid
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tRNA tRNA
tRNA
empt
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Figure 1.6: Simplified illustration of Translation.
In essence the ribosome translates the genetic code from the mRNA into proteins, and
hence the name Translation. They do this by forming a chain of amino acids. This chain
of amino acids, also known as a polypeptide, is constructed according to the sequence of
bases in the mRNA. The mRNA binds to one active site of the ribosome, while tRNA’s
which carry one amino acid each, bind to another site. The amino acids are then bound
together according to how the complimentary bases on the mRNA and tRNA fit together.
This is the process known as translation , i.e. the ribosome translates the genetic infor-
mation from the mRNA into proteins. Figure 1.6 illustrates this. Translation is part of the
overall process of gene expression.
1.2.3 Gene expression and gene expression profiling
The process of gene expression is the primary mechanism by which an organisms geno-
type results in the phenotype; a gene is expressed and the products from this (such as
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proteins) give rise to the organisms phenotype, such as eye colour, hair colour, disease
status etc.
The term gene expression describes the process by which information from the gene
is transcribed into a functional gene product. There are essentially two types of func-
tional gene products; coding RNA (mRNA) and hence proteins and non-coding, func-
tional RNA’s such as tRNA and rRNA. Genes are up or down regulated, or turned on or
off in response to some stimulus; for example from a regulatory gene whose job is to
turn other genes on or off, or from a signal outside of the cell, for example some hor-
mone. Gene expression is a process which encompasses Transcription and Translation,
along with some other modulated processes, such as the post translational modification of
the protein product, whereby the proteins ‘three dimensional’ structure is formed. How-
ever, in the context of statistical analyses and methodologies it is mainly Transcription
and Translation that are of interest, or more strictly the products of these processes, i.e.
mRNA and protein.
1.2.4 Quantifying gene expression
The level of expression of a given gene can be measured by determining the number of
mRNA molecules produced by that particular gene. A DNA microarray can be used to
measure the amount and type of mRNA transcripts present in a sample of cells (blood or
tissue). The microarray generally consists of a solid surface made of glass, silicone or
nylon to which in specific positions, strands of DNA are attached, these sites are often
referred to as probes. Other microarrays, for example Illumina, use microscopic beads
instead of a solid platform. Microarrays quantify gene expression by measuring the hy-
bridization of the mRNA from the sample under study to the DNA microarray. Each
hybridization can be seen as a separate experiment at each probe on the microarray.
There are many ways in which the microarray is designed and in which hybridization
is measured, some of which are discussed in detail by Parmigiani et al. (2003). Measure-
ment of hybridization will not be discussed in detail in this thesis. Once data has been
collected from a microarray, it must then be standardized in some way such that data is
on a common scale and experimental error is minimal. This standardization is known as
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normalization. There is often a second level of standardization whereby expressions are
transformed to follow a standard N(0,1) distribution. This second level of standardization
is generally carried out for ease of analysis.
1.3 Analysis of gene expression data
Modelling gene expression data presents two major problems. Firstly, we have the prob-
lem of identifying the group of genes from the thousands of possible candidates that are
responsible for a given phenotype. Secondly, we have the problem of determining and/or
interpreting how this group of genes affects phenotype.
A typical gene expression data set would consist of the expression of some large num-
ber of genes, N, being measured over some relatively small number of subjects, n, across a
number of conditions, for example cancer versus non-cancer. Traditional genomics stud-
ies often focus on a gene by gene analysis; attempting to relate single genes to phenotype.
There are considerations to take into account with such an approach, such as multiple
hypothesis testing issues and reliability and interpretation of results Subramanian et al.
(2005). It is often unpractical to overcome such problems.
An interesting and useful tool for investigating relationships between gene expression
and phenotype is the analysis of sets of genes. There are many published methods for the
analysis of gene sets, but prior to going into details of these methods, it is necessary to
study the origins of such methods. Individual gene analysis (IGA), as coined by Nam and
Kim (2008), is at the root of many if not all methods and models for the analysis of gene
sets.
1.3.1 Individual gene analysis (IGA): A typical gene association study
Since the introduction of microarray technology in around 1995, it has been of great
interest to identify differentially expressed genes with regard to phenotype or genotype
and from this infer on biological processes within the cell. To this end many statistical
methods have been developed. The most widely used approach, commonly known as
individual gene analysis (IGA) is carried out as follows
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1. Calculate some metric of effect of every gene on phenotype. For example t-test test
statistic.
2. Calculate corresponding p-values, often using some multiple testing correction, and
order from low to high.
3. Choose either some arbitrary cut off for p-values or some arbitrary number of top
ranking p-values to determine a list of significant genes.
4. Used pathway annotation files to determine whether there are significantly large
numbers of these significant genes in a certain pathway.
The first point of statistical interest is point 2, or more specifically in methods that
control or correct for multiple testing. The second point of statistical interest is in deter-
mining if the top-ranking list of genes is overrepresented in particular gene sets. To this
end, some of the methods that control and account for multiple hypothesis testing on such
a scale are described. Following this point 4 is considered.
When performing such testing on large data there will be many false positive results
simply by chance, and so considerations of how to control or account for these false
positive results must be made. Traditionally, control of the family wise error rate was
considered sufficient, however it can be shown that control of the family wise error rate
(FWER) can be overly conservative when dealing with such large numbers of tests. More
recently false discovery rate (FDR) procedures have been used to account for multiple
testing on such large scales and have been used with much success, for example Efron
et al. (2001), Efron and Tibshirani (2002) and Mootha et al. (2003). This section contin-
ues to introduce and describe some of the methods used to monitor and correct for false
positive results when performing analyses such as IGA.
1.3.1.1 Family-wise error rate (FWER)
Testing a single hypothesis can result in two types of error
• Type-1 error: To falsely reject the null hypothesis.
• Type-2 error: To falsely fail to reject the null hypothesis.
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This is demonstrated below in Table 1.1.
Test Declared
Non-significant Significant
H0 Correct Type-1 error
Truth
H1 Type-2 error Correct
Table 1.1: Errors in hypothesis testing
Testing relies on control of the type-1 error rate. This is achieved by specifying the
level, α , which is the probability of making a type-1 error. In practice the p-value, which
is defined as the probability of observing something as or more extreme than the observed
test statistic given that H0 is true, is compared to α to determine whether to reject or
fail to reject the null hypothesis. Suppose we took m sample sets, where each sample
is comprised of n1 subjects from a population with condition 1 and n2 subjects from a
population with condition 2. If a test is conducted between the two conditions on each of
the m sets then we are testing m null hypothesis, H01,H02, . . . ,H0m, and so by chance we
will make some errors in our conclusions. Table 1.2 illustrates the sum of the results from
the m tests.
Test Declared
Non-significant Significant Total
H0 U V m0
Truth
H1 T S m−m0
Total m-R R m
Table 1.2: Numbers of errors in testing m hypotheses.
As can be seen in Table 1.2 V is the number of type-1 errors and T is the number of
type-2 errors. The family-wise error rate (FWER) is defined as the probability of making
at least one type-1 error.
FWER = P[V ≥ 1] (1.1)
The FWER can be better defined in terms of if the null hypotheses are indeed true.
• The FWER under the complete null (FWEC), given by (1.2), is the probability that
at least one type-1 error occurs given that all the null hypotheses are true.
FWER = P[V ≥ 1|H01,H02, . . . ,H0m true] (1.2)
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If the FWEC is less than or equal to α then the test procedure is said to control the
FWER in the weak sense.
• The FWER under a partial null (FWEP), given by (1.3), is the probability that at
least one type-1 error occurs given that a subset of the null hypotheses, call them
Hs0, are true.
FWER = P[V ≥ 1|Hs0 true] (1.3)
A test procedure is said to have strong control of FWER when the FWEP is less
than or equal to α under all subsets of the null hypotheses. Strong control implies
FWEP≤ α for all partial nulls.
Suppose we conduct m hypothesis tests H01,H02, . . . ,H0m, and it is specified that each
test be controlled at level α . So for any test, the probability of falsely rejecting the null
hypothesis (or the type-1 error rate) is less than or equal to α , i.e.
P[reject H0i|H0i true]≤ α for i=1,2,. . . ,m (1.4)
Assume that the tests are independent of one another. Then the probability of rejecting a
test is independent of the outcomes of the other m-1 tests. Say we reject n null hypotheses,
then the probability of falsely rejecting at least one null hypothesis is given by (1.5)
FWER = P[n≥ 1|H01,H02, . . . ,H0m true]
= 1−P[n = 0|H01,H02, . . . ,H0m true]
= 1−
m
∏
i=1
P[fail to reject H0i|H0i true]
= 1−
m
∏
i=1
(1−P[reject H0i|H0i true])
≤ 1−
m
∏
i=1
(1−α)
≤ 1− (1−α)m (1.5)
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So for example if five tests were conducted at the 5% level, then the probability of making
at least one type-1 error would be
1− (1−0.05)5 = 0.23 (1.6)
A widely used method to control the FWER when testing multiple hypotheses is Bonfer-
roni adjustment. A brief outline of Bonferroni adjustment, which controls the FWER in a
weak sense, follows.
The Bonferroni adjustment to control the problem outlined previously is very simple.
If we require a significance level α then the Bonferroni adjustment would use (1.7)
α ′ =
α
m
(1.7)
instead of α as the significance level for each individual test. If each test is controlled
at the α ′ level then the overall FWEC will be controlled at the α level. The Bonferroni
correction is based on the result that
P[reject H01, reject H02, . . . , reject H0m]≤P[reject H01]+P[reject H02]+. . .+P[reject H0m]
(1.8)
with equality if the events are mutually exclusive. So if we set P[rejectH0i] = α ′, then
FWER≤ mα ′.
In the context of gene expression studies the Bonferroni correction to p-values can
be overly stringent and can often result in many false negatives. For example, say we
had 20,000 probes and were carrying out a single gene analysis on cancer status; for a
probe/gene to be significant at the 5% level using the Bonferroni correction method, a
p-value of 2.5e-06 would have to be achieved. There is also the question of how to choose
α ′ to minimize false positives and false negatives with reasonable justification. The use
of the false discovery rate is more suitable in the context of gene expression studies.
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1.3.1.2 False discovery rate (FDR)
In recent years, false discovery rate (FDR) methods have become synonymous with many
high dimensional model selection procedures and multiple-hypothesis testing problems.
The FDR is defined as the ratio between the number of type-1 errors and the total
number of tests that are significant, or alternatively as the proportion of rejected null
hypotheses which are erroneously rejected. Suppose that it is required to test m null
hypotheses, of which m0 are true. This situation is summarized in the FWER section
in Table 1.2. It is assumed that R is an observable random variable and S, T, U, V are
unobservable random variables. Then the FDR is defined as
FDR = E
[
V
R
∣∣∣∣R > 0]P[R > 0] (1.9)
which is the expectation of the unknown and unobservable random variable
V/R (1.10)
where V/R≡ 0 if R = 0. There are two important properties of this error rate;
1. Suppose that all null hypotheses are true; V = R and so
V/R =

0 if V = 0
1 if V ≥ 1
(1.11)
Then we have (1.12)
E[V/R] = 0×P[V = 0]+1×P[V ≥ 1]
= P[V ≥ 1]
= FWER (1.12)
so if all null hypotheses are true, the FDR and the FWER are equivalent. Therefore
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control of the FDR implies weak control of the FWER.
2. When it is not the case that all null hypotheses are true (R > 0), we have
E[V/R] = E[V/R|V ≥ 1]P[V ≥ 1]+E[0/R|V = 0]P[V = 0]
= E[V/R|V ≥ 1]P[V ≥ 1]
and since V < R
E[V/R]< P[V ≥ 1] (1.13)
Therefore, in general the FDR is less than or equal to the FWER, which implies that
if an approach controls the FWER then the FDR will be under control. However, if
an approach controls only the FDR it can be more flexible and can lead to a gain in
power.
Again lets suppose that we require m null hypotheses to be tested simultaneously, with
the null hypotheses given by
H01,H02, . . . ,H0m (1.14)
With corresponding test statistics
z1,z2, . . . ,zm (1.15)
and p-values
p1, p2, . . . , pm (1.16)
Benjamini and Hochberg (1995) introduced the following procedure to control the number
of false discoveries;
• Order the p-values from smallest to largest, so that we have
p(1), p(2), . . . , p(m) (1.17)
and denote H(0i)as the null hypothesis corresponding to the ordered p-value p(i)
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• Let
k = max
(
i : p(i) ≤ q
i
m
)
0 < q < 1
then all null hypotheses corresponding to p(1), . . . , p(k) are rejected. It can be shown
that when the test statistics are independent this procedure controls E[V/R] at level
≤ q.
From this procedure comes the Benjamini-Hochberg rule (BH rule (1.18)), which is a
simple correction of p-values;
pBHi = pi
m
order(pi)
i = 1,2, . . . ,m (1.18)
Where
• pBHi - The BH rule corrected p-value for the ith ordered p value.
• order(pi) - Equals m for the largest p-value and one for the smallest p-value and so
on.
• If order(pi)m ≤ pi then pBHi = 1
The BH rule can be formulated in terms of an empirical Bayes procedure. Suppose that it
is small values of z that lead to rejection of H0. Under the null hypothesis, for a particular
test P[Z ≤ z|null] = p. In general P[Z ≤ z] = order(z)/m can be used as an empirical
cumulative distribution function for z. If we specify the prior prbability for H0 being true
as p0 so that, in an obvious notation, P[null] = p0, applying Bayes theorem we have
P[null|Z ≤ z] = P[Z ≤ z|null]P[null]
P[Z ≤ z]
=
p0 p
order(z)/m
For the ith order statistic this becomes
P[null|Z ≤ zi] = p0 piorder(zi)/m
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If we choose to declare significant if this is less than α , then p0 pi/m < α and so
p <
i
m
α
p0
this is the BH rule with q = α/p0.
The BH rule is popular due to its simplicity, however, it can often be a conservative
estimator of the Fdr. One way to improve the BH rule is to use a more appropriate estimate
of p0. This leads directly to the well-known q-values that are commonly used for large
scale multiple testing. There are various methods for the estimation of p0, some of which
are discussed by Storey (2002).
More generally, following Efron (2005), assume that the m tests are divided into the
classes null, or non-null, occurring with prior probabilities p0 and p1 = 1− p0 respec-
tively. Also assume that the densities of the test statistics are different depending upon
class. This information is summarized below;
p0 = P[null] and null density f0(z)
p1 = P[non-null] and non-null density f1(z) (1.19)
Where z is some test statistic. Also let F0 and F1 be the cumulative distribution functions
(cdf’s) for f0 and f1 respectively. Consider the two component mixture density.
f (z) = p0 f0(z)+ p1 f1(z) (1.20)
The null density f0 corresponds to the ‘uninteresting’ test statistics, whereas f1 is an
unspecified alternative density for the ‘interesting’ test statistics. The corresponding CDF
is given by
F(z) = p0F0(z)+ p1F1(z) (1.21)
The posterior probability of a case being null given that its z-value Z is less than some
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value z is given by (1.22)
Fdr(Z) = P[null|Z ≤ z]
=
p0F0(z)
F(z)
(1.22)
Note that in the above only the left hand tail areas have been considered, but right hand
tail areas and both tail areas could just as well be used.
The aim of most investigations involving large numbers of multiple comparisons is to
identify a relatively small set of interesting non-null cases. Because of this, a large value
of p0 is often assumed such as p0 ≥ 0.9 Efron (2005) (Note: the BH rule uses p0 = 1
along with the empirical form of F1 for p-value corrections).
For practical implementation of the methodology described above p0, f0 and f1 are
required. In particular, a uniform distribution over [0,1] would be appropriate if p values
were used for z. There is a substantial body of literature on methods for obtaining p0, f0
and f1 and this is a research topic in its own right. See, for example, Storey (2002), Efron
and Tibshirani (2002), Storey (2003).
False discovery methods are increasingly being applied in the analyses of genetic
data to account for such problems, some examples of its use are Efron et al. (2001),
Efron and Tibshirani (2002) and Benjamini et al. (2009) gives a great overview of the
method of false discovery rates as applied to SNP data. The FDR is also used in Gene
Set Enrichment Analysis (GSEA) (See Chapter 2) as described in Mootha et al. (2003)
and Subramanian et al. (2005). A particularly good piece of software for FDR analyses
is the fdrtool package in R Strimmer (2008). Having outlined the key concepts, this
methodology is not pursued further in this thesis, the main focus of which is a Bayesian
analysis of gene expression data.
1.3.1.3 Tesing for enrichment
After any p-value corrections have been made and a list of top-ranking genes selected,
it needs to be determined whether any particular gene sets are over-represented in that
list. One such method to determine the over-representation of a gene set amongst the top-
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ranking differentially expressed genes is with the use of a 2× 2 contingency table. The
2×2 contingency table is constructed as shown in Table 1.3
Differentially expressed gene Non-differentially expressed gene Total
In gene set nGD nGDc nG
Not in gene set nGcD nGcDc nGc
Total nD nDc n
Table 1.3: 2× 2 contingency table for assessing over representation of differentially expressed
genes in a gene set. nGD denoting the number of genes in the set that are differentially
expressed and so on.
A number of different tests are proposed to test for independence in Table 1.3, for
example the χ2 test. Khatri and Draghici (2005) provide a detailed account of such IGA
methods.
There are several limitations with such a gene-by-gene analysis even after such p-
value corrections as described previously are made. These limitations are:
• After correction for multiple hypothesis testing there may not be any significant
genes/probes. For example, suppose we had 20,000 probes and were carrying out
a single gene analysis on cancer status; for a probe to be significant at the 5%
level using the Bonferroni correction method, a p-value of 2.5e-06 would have to
be achieved. This means that even with relatively large sample sizes effect sizes
have to be large to obtain significance;
• There may be many significant probes/genes even after correction on p-values with
no discernible biological theme thus making any interpretation of results very diffi-
cult;
• IGA assumes independence of gene effects on phenotype, which is not realistic and
will increase false positive results;
• There may be a highly significant pathway effect, which a single gene analysis
would not show and in some cases the single probes/genes in the pathway would
not be significant on their own;
• The cut-off threshold for the inclusion of genes into the top ranking list is com-
pletely arbitrary, and can be shown to severely affect results Pan et al. (2005).
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Clearly other methods and models, such as Pathway analysis, also known as gene set
analysis, will be more useful for studies aiming at relating pathways to phenotype.
1.3.2 Pathway analysis
A typical frequentist analysis of sets of genes would take some measure of individual gene
effect on phenotype, summarize these individual gene effects into some measure of gene
set effect, then produce a p-value against some null hypothesis of no gene set effect. It is
well known and accepted that genes and hence proteins function in concert to affect phe-
notype and so it makes sense to construct models to mimic such processes. Such models
allow the experimenter to utilize previously accrued biological knowledge to provide a
more biologically informed analysis. Analyzing functionally dependent groups of genes
rather than single genes not only allows the experimenter an immediate interpretation to
any positive results, but results from such analyses are generally more robust, Mootha
et al. (2003), Efron and Tibshirani (2006). These functionally dependent groups of genes,
known as gene sets, are defined on the basis of prior biological knowledge, such as loca-
tion on the chromosome. There are many freely available databases defining gene sets,
such as Gene Ontology, Ashburner et al. (2000) or the Kyoto encyclopedia of genes and
genomes (KEGG), Ogata et al. (1999). The Molecular Signatures data base (MSigDB),
which is available at http://www.broadinstitute.org/gsea/msigdb/index.jsp,
gathers many of these pathway databases into one place, identifying some areas in which
the databases of gene sets may be more applicable and more conducive to determining
results relative to the study.
It seems as though there are, broadly speaking, three general ways of approaching
a gene set analysis. These are defined by the hypothesis which they are testing. These
hypotheses are:
• H10 : The genes in set s are at most as often differentially expressed as the genes not
in set s;
• H20 : None of the genes in set s are differentially expressed;
• H30 : None of the gene sets are associated with phenotype.
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H10 and H
2
0 are defined by Goeman and Buhlmann (2007) as competitive and self con-
tained null hypotheses respectively, Nam and Kim (2008) provide comprehensive details
of the methods testing such hypotheses. Gene set enrichment analysis (GSEA), as intro-
duced by Mootha et al. (2003) and developed by Subramanian et al. (2005) defines the
third hypothesis.
GSEA is the most widely used method for the analysis of sets of genes and from here
on the frequentist methods looked at will focus on GSEA and its derived methods. Several
methods originate from GSEA, such as Gene Set Analysis (GSA) Efron and Tibshirani
(2006) and those introduced by Jiang and Gentleman (2007) and they follow a general
framework:
1. Suppose we have genes g = 1,2, . . . ,N;
2. Begin with a pre-defined collection of gene sets s, s = 1,2, . . . ,k;
3. Compute some test statistic zg for all g = 1,2, . . . ,N genes;
4. Let zs = (zs1,zs2, . . . ,zsms) be the vector of length ms of test statistics for the genes
g = 1,2, . . . ,ms in set s;
5. Compute some gene set score s(zs) for each of the k gene sets;
6. Create a null distribution for the gene set scores and test whether the true scores
(s(zs)) are in the extremes of the null distribution.
The way in which this general outline differs from method to method is in the construc-
tion of zg, s(zk) and of the null distribution. Clearly, this is a somewhat ad-hoc approach,
with no formal modelling involved. To set the problem of analyzing sets of genes into
a formal, distribution based model would allow the experimenter to break down the real
biological processes behind pathways into sensible, reasoned stages that could be repre-
sented by distributions. It would also allow us to discard these different null hypotheses
in favour of Bayesian posterior probabilities. The use of Bayesian probabilities also re-
moves the need for the definition of arbitrary cut offs on p-values to determine significant
gene sets. There are several Bayesian approaches to the analysis of gene sets such as
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Stingo et al. (2011) and Bayesian gene set analysis (BGSA) as presented by Shahbaba
et al. (2011). However, there is still much scope for the development and application of
Bayesian, model based approaches to the problem of analyzing sets of genes. The rich
area of research of Bayesian Pathway analysis provides a great motivation for this thesis.
Some established gene set analysis methods will be discussed in detail in Chapter 2.
In order to fully appreciate some of these Bayesian methods and to possibly develop
new methods, a grounding in Bayesian statistics is required. The following section out-
lines such methods, along with other statistical methodology that will be used in this
thesis.
1.4 An overview of other relevant statistical methods
The following section presents an outline to some of the more general statistical tools and
concepts to be used in the thesis.
1.4.1 The Receiver Operator Characteristic (ROC) Curve
The ROC curve is a graph that allows us to asses the performance of a classification rule.
Typical ROC analyses are concerned with a two by two classification table which results
from cross classifying the true class of each object by its predicted class. For example a
typical two by two situation might be that we construct a probabilistic model which gives
the risk that a subject given their data has some disease of interest, then our classification
rule c(x) uses some threshold T=t to classify whether a subject is in the disease class, call
it c1, or the unaffected class, call it c2 due to the computed probability from the model,
i.e. a subject with probability p > t is classified as being in c1 and conversely a subject
with probability p ≤ t is classified as being in c2. Then the possible classifications are
demonstrated in Table 1.4 More generally, say we get some score s from our model for
each subject, which again is classified due to some threshold. The joint probabilities of
these classifications are shown below in Table 1.5
There are different ways in which the performance of a classification rule can be
assessed due to how the above joint probabilities are summarized. In an ROC analysis
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Classified
c1 c2
c1 True positive (tp) False negative (fn)
Truth
c2 False positive (fp) True negative (tn)
Table 1.4: The cross classification of the true class of an object by its predicted class in a two by
two classification situation.
Classified
c1 c2
c1 P[s > T,c1] P[s≤ T,c1]
Truth
c2 P[s > T,c2] P[s≤ T,c2]
Table 1.5: Probabilities of cross classification of the true class of an object by its predicted class
in a two by two classification situation.
these probabilities are summarized as
• P[s > T |c1] - This is known as the true positive rate or detection rate.
• P[s > T |c2] - This is known as the false positive rate.
• P[c1], P[c2] - marginal probabilities of belonging to either class.
Then the ROC curve is constructed by plotting the true positive rate against the false
positive rate with varying threshold T. The idea behind the ROC curve is to provide a
summary of the performance of a classifier over the whole range of possible classification
thresholds. The ROC curve will generally be a continuous curve lying in the upper triangle
of the plot area. The closer to the upper left hand corner the better the performance of the
classifier and the closer to a straight line through (0,0), (1,1) the worse the performance
of the classifier.
Now, if the two populations are identical then there is equal probability of classifying
a subject into either c1 or c2 i.e. P[s|c1] = P[s|c2], so as t varies the true positive rate will
always equal the false positive rate, and therefore the ROC curve will be a straight line
through the origin with gradient one. This line is known as the chance diagonal and is
often added to ROC plots to see how different classification is from completely random.
Alternatively, if there is a complete separation between the two groups, then for all t the
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true positive rate will be one and the false positive rate will be zero and the ROC curve
will follow the x and y axes.
1.4.1.1 Area under the ROC curve (AUC)
The AUC is defined as the area under the ROC curve. Lets consider AUC in the two
extreme cases of an ROC curve;
• Perfect separation (where the ROC curve is a line from x=0, y=0 to x=0, y=1 to
x=1, y=1)-Then the AUC is the area of a one by one square, i.e. AUC=1.
• Random allocation (ROC curve is a line through (0,0) with gradient one)-Then
the AUC is the area of a right angled triangle with height one and width one, i.e.
AUC=0.5.
So, the upper bound of the AUC is 1 and the lower bound of the AUC is 0.5; the higher
the AUC the better the classifier. An intuitive interpretation of AUC is that the AUC is the
average tp rate taken over all possible fp rates. Another useful interpretation is that if sc1
and sc2 are scores given to randomly, independently chosen subjects from c1 and c2 then
AUC = P[sc1 > sc2] (1.23)
1.4.2 Bayesian Statistics
The Bayesian approach to statistical inference draws conclusions about model or popu-
lation parameters from data. Bayesian inference differs from the frequentist approach in
that inference is based upon f (θ |x) rather than f (x|θ). In essence parameters are consid-
ered random variables, rather than fixed quantities.
Say we have parameter θ which we wish to make inference about and a likelihood
function f (x|θ) which measures the probability of observing data x under parameter val-
ues θ , also say we have some prior knowledge of θ , f (θ), then we can obtain a full
probability model
f (x,θ) = f (x|θ) f (θ) (1.24)
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then having observed data x then the conditional distribution of θ can be determined using
Bayes theorem
f (θ |x) = f (x|θ) f (θ)∫
f (x|θ) f (θ)dθ (1.25)
The conditional distribution f (θ |x) is known as the posterior distribution and is at the
heart of all Bayesian inference. In many cases
∫
f (x|θ) f (θ)dθ is intractable and by far
the most popular techniques to overcome such problems are Markov chain Monte Carlo
(MCMC) methods.
1.4.3 Markov chain Monte Carlo (MCMC)
In many modern applications there is the need to integrate over highly dimensional prob-
ability models in order to make inference about model parameters. Markov chain Monte
Carlo (MCMC) techniques provide solutions to such problems and therefore give great
scope for realistic, complex statistical modelling. Essentially, MCMC uses Markov chains
to implement Monte Carlo integration.
1.4.3.1 Monte Carlo integration
Monte Carlo integration evaluates E[ f (X)] by drawing samples Xt , t = 1,2, . . . ,n from
pi(·) and evaluating E[ f (X)] by
E[ f (X)]≈ 1
n
n
∑
t=1
f (Xt) (1.26)
In essence the population mean is estimated by a sample mean. The sample, Xt , can be
generated in any way which draws samples from pi(·). One specific way of doing this is
by a Markov chain with pi(·) as its stationary distribution.
1.4.3.2 Markov chains
A Markov chain is a sequence of random variables X0,X1,X2, . . . whereby at any time
t ≥ 0 the next state in the chain Xt+1 is sampled from a distribution P(Xt+1|Xt). P(·|·) is
known as the transition kernel of the chain. In essence Xt+1 depends on Xt only and does
not depend on further history of the chain.
Subject to certain regularity conditions, the chain will eventually forget its starting
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value and P(Xt |X0) will converge to some unique stationary distribution, independent of t
or X0. As t increases the sampled points will look more and more like dependent samples
from the stationary distribution.
1.4.3.3 The Metropolis Hastings algorithm
The aim of the Metropolis-Hastings algorithm is to build a Markov chain on X starting
at some initial value X0. For the Metropolis-Hastings algorithm, at each state Xt , the next
state Xt+1 is chosen by sampling a candidate point Y from some proposal distribution.
The candidate point Y is then selected with probability α(Xt ,Y )
α(Xt ,Y ) = min
(
1,
pi(Y )q(Xt |Y )
pi(X)q(Y |Xt)
)
(1.27)
If Y is accepted, then the next state in the chain becomes Xt+1 =Y , if not then the next
state becomes Xt+1 = Xt . As the target distribution pi(·) only enters the algorithm through
the ratio pi(Y )/pi(X) then knowledge of the posterior distribution only up to a normalizing
constant is required.
Essentially the Metropolis-Hastings algorithm works as follows There are many possi-
Algorithm 1.1 The Metropolis-Hastings algorithm
1. Arbitrarily select some starting value X0
2. Sample a candidate point Y from some proposal distribution q(Y |Xt)
3. Compute the acceptance probability α(Xt ,Y ) using (1.27)
4. Sample u from a uniform distribution U(0,1).
5. If u≤ α(Xt ,Y ) then Xt+1 = Y , else Xt+1 = Xt
6. Increment t and return to step 2.
ble choices for the proposal distribution q. Two of the most common choices are outlined
below.
1.4.3.3.1 1. The Independence sampler For all X , let q(Xt ,Y ) = q(Y ) for some prob-
ability density q(·). In essence the proposal density is independent of the current value Xt .
This idea is similar to rejection sampling, in that we sample from one probability density
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q(·) and then accept or reject the samples as coming from the probability density pi(·).
This method works well when we can find a simple probability density q(·) which closely
approximates pi(·). In this case the acceptance probability can be written
α(Xt ,Y ) = min
(
1,
w(Y )
w(Xt)
)
(1.28)
where w(Xt) = pi(Xt)/q(Xt) denotes the relative weights of the two densities at x.
1.4.3.3.2 2. Random-walk Metropolis Suppose that we are currently at Xt . In sta-
tionarity it is likely that Xt has high posterior probability. Random-walk Metropolis, there-
fore, samples proposal values from a proposal density that is centered about the current
value Xt . If the proposal density is symmetric about Xt then the acceptance probability
can be written as follows.
α(Xt ,Y ) = min
(
1,
pi(Y )
pi(Xt)
)
(1.29)
1.4.3.4 The Gibbs sampler
The Gibbs sampler obtains samples from the multivariate distribution θ = (θ1,θ2, . . . ,θn)
by successively and repeatedly simulating from the conditional distributions of each com-
ponent given the other components. In general the Gibbs sampler algorithm is as follows
in Algorithm 1.2
Algorithm 1.2 The Gibbs sampler algorithm
1. Initialize with θ = (θ (0)1 ,θ
(0)
2 , . . . ,θ
(0)
n .
2. Simulate θ (1)1 from the full conditional θ
(1)
1 |θ (0)2 , . . . ,θ (0)n .
3. Simulate θ (1)2 from the full conditional θ
(1)
2 |θ (1)1 ,θ (0)3 , . . . ,θ (0)n .
4. Simulate θ (1)n from the full conditional θ
(1)
n |θ (1)1 ,θ (1)2 , . . . ,θ (1)n−1.
5. Iterate.
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1.4.3.5 Burn in
Typically, the starting value for a Markov chain will not be drawn from its stationary
distribution. Therefore burn in is required such that the chain can converge to its stationary
distribution before samples from the chain can be used. The length of burn in depends
on the starting value of the chain, the rate of convergence of the chain and how similar
the proposal distribution is to the stationary distribution. There is no hard and fast tool
for determining burn in and visual inspection of trace plots is still the the most commonly
used method, however, this method does have its drawbacks, for example in multi modal
distributions.
1.4.3.6 Monitoring Convergence
A general approach to monitoring the convergence of Markov chains, as introduced by
Gelman and Rubin (1992), is based upon identifying whether the chain has ‘forgotten’ its
starting point. This can be implemented by comparing several parallel sequences initiated
at different starting values and determining whether they are distinguishable.
The most obvious and widely used approach to convergence assessment is to look
at trace plots of the given sequences. However, this can be misleading in multi-modal
distributions and some prefer a more quantitative approach to convergence monitoring.
Gelman and Rubin (1992) introduce a quantitative approach to convergence monitor-
ing based upon the Analysis of Variance (ANOVA), whereby approximate convergence
can be diagnosed when the within chain variance of several parallel sequences, initiated
at different starting points, is no greater than the between chain variance. Say we have m
parallel sequences, each of length n with realizations Xi j i = 1,2, . . . ,m, j = 1,2, . . . ,n
then the between chain variance is given by
B =
n
m−1
m
∑
i=1
(X¯i•− X¯••)2 (1.30)
where
X¯i• =
1
n
n
∑
j=1
Xi j and X¯•• =
1
m
m
∑
i=1
Xi•
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and the within chain variance,W , is given by
W =
1
n
m
∑
i=1
s2i (1.32)
where
si =
1
n
n
∑
j=1
(Xi j−Xi•)2(1.33)
B (1.30) contains a factor of n because it is based on the variance of the within se-
quence means, X¯i•, each of which is an average of n values. From the two variance com-
ponents (1.30) and (1.32), we construct two estimates of the variance of X in the target
distribution.
1.
ˆvar(X) =
n−1
n
W +
1
n
B (1.34)
is an estimate of the variance if the starting points of each chain were drawn from
the target distribution, i.e. it is an estimate of the variance that is unbiased under
stationarity. This will generally be a conservative estimate (over estimate) under
the more realistic assumption that the starting points are over-dispersed.
2. The within chain variance, W (1.32), is taken as the second estimate of variance.
The within chain variance, for finite n, will be an underestimate of the variance of
X as individual chains will not have had time to cover all of the target distribution.
Note that as n→∞ both ˆvar(X) and W will approach var(X), but from different direc-
tions.
The convergence of Markov chains can be monitored by calculating the ratio between
the estimated upper and lower bounds for the standard deviation of X , coined the ‘esti-
mated potential scale reduction factor’
√
Rˆ =
√
ˆvar(X)
W
(1.35)
As simulation converges, the potential scale reduction factor decreases to 1 and the paral-
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lel chains are overlapping. If Rˆ is large then it is wise to run the chains for longer.
1.4.4 Bayesian Model Comparison
Using the MCMC techniques outlined above, posterior samples for many complex mod-
els can be obtained and convergence can be assessed. However, it is often desirable to
compare models and assess model fit and adequacy. Below are discussed two methods
for Bayesian model comparison; the Deviance information Criterion (DIC) and Bayes
Factor (BF).
1.4.4.1 Deviance information Criterion (DIC)
The DIC is a hierarchical modelling generalization of the Akaike information criterion
(AIC) and Bayesian information criterion (BIC). It can be particularly useful in the com-
parison of Bayesian models where posterior distributions of the models are obtained by
MCMC simulation.
It is first useful to define deviance. Deviance (D) can be used as a measure of model
fit and can be defined for the likelihood f (x|θ), as
D(θ) =−2log f (x|θ) (1.36)
where x are the data and θ are unknown parameters. The posterior mean deviance is often
used as a measure of fit for Bayesian models, where the posterior mean deviance D¯ is
given by
D¯ = E[D(θ)] (1.37)
This is a particularly straightforward quantity to calculate within MCMC steps and pro-
vides an accurate measure of model fit. However, there will be an infinity of models that
fit the data equally well, hence the true model will be indistinguishable from an infinity
of correct models. We want the most simple correct model i.e. the model with the least
number parameters. Therefore some measure of model complexity is needed to trade off
against D¯
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If we define θˆ = E[θ |x], then a model complexity term can be defined as
pD = Eθ |x[D]−D(Eθ |x[θ ]) (1.38)
which is essentially the posterior mean deviance minus the deviance evaluated at the pos-
terior mean of the parameters.
Then the DIC is defined as
DIC = D¯+ pD (1.39)
models with smaller DIC are better supported by the data.
1.4.4.2 Bayes Factors
Suppose we wish to compare how models M1 and M2 with parameters θ1 and θ2 respec-
tively fit data x. Marginal distributions of x can be found by integration
f (x|Mi) =
∫
f (x|θi,Mi) f (θi)dθi i = 1,2 (1.40)
where f (θ) is the prior density for θ . Then using Bayes theorem and defining prior
densities for the given model, posterior model probabilities can be obtained
f (Mi|x) = f (x|Mi) f (Mi)f (x) i = 1,2 (1.41)
Then the Bayes Factor (BF) is given by
BF =
f (M1|x)/ f (M2|x)
f (M1)/ f (M2)
=
f (x|M1)
f (x|M2) (1.42)
Which can be thought of as the ratio of the posterior odds of M1 to the prior odds of M1.
Assuming the models are a priori equally probable (i.e. f (M1) = f (M2) = 0.5) then we
have
BF =
f (M1|x)
f (M2|x) (1.43)
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Considering the case where both models have the same parameterization, i.e. θ1 =
θ2 = θ then the Bayes Factor is simply the likelihood ratio between the two models.
Values of B > 1 indicate more support for M1 under the data and conversely values of
B < 1 indicate more support for M2 under the data.
There are other such Bayesian model comparison metrics, such as the Bayesian In-
formation Criterion (BIC). Although these model comparison measures are useful, it is
preferable to have an automatic model selection procedure. Reversible jump Markov
chain Monte Carlo (RJMCMC) provides not only a model comparison measure, in the
form of a posterior model probability, but also performs model selection. RJMCMC is
outlined in detail in Chapter 5.
1.5 Outline
The rest of the thesis is as follows. Chapter 2 is devoted to setting the scene and proceeds
to discuss in detail and critically appraise three of the more prominent methodologies for
the analysis of gene sets, these being GSEA, Gene Set Analysis (GSA) and Bayesian
Gene Set Analysis (BGSA). Through discussion it can be seen that all three methods
are preferable to IGA. It can also be seen, however, that there are some flaws with the
methods, in particular where the methods do not overcome some of the problems with
IGA.
Chapter 3 presents a thorough simulation study comparing GSEA, GSA and BGSA.
Whereby data simulation models are first discussed in order to decide upon the data sim-
ulation model that produces realistic data. Several scenarios concerning ‘activeness’ of
gene set are then defined in such a way that aims to highlight the relative strengths and
weaknesses of GSEA, GSA and BGSA. The methods are then applied to such data and
results discussed. A second, more practically based appraisal can then be made of the
three methods.
Chapter 4 proposes a hybrid Bayesian/ frequentist model that builds upon issues raised
in Chapters 2 and 3. Chapter 4 also develops a MCMC algorithms to fit this model.
Chapter 5 introduces and defines two Bayesian models for the analysis of gene sets,
32
these being Bayesian Analysis of Gene Sets (BAGS) and Multivariate Bayesian Analysis
of Gene Sets (MVBAGS). Chapter 6 compares the introduced methods to GSEA, GSA
and BGSA in some case studies based upon data simulated according to the approach
outlined in Chapter 3.
Chapter 7 applies the BAGS model to a real data set. This data set, known as the p53
data set, is freely available at http://www.broadin stitute.org/gsea/datasets.jsp.
Subramanian et al. (2005), Efron and Tibshirani (2006) and Shahbaba et al. (2011) present
results of analyses of the p53 data set, and we compare these results to those obtained by
applying BAGS to the data.
Finally Chapter 8 discusses the work presented in this thesis and indicates future work
in the areas discussed.
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Chapter 2
Some existing methodologies for gene set
analysis
2.1 Introduction
A typical gene expression data set would consist of the expression of some large number
of genes, N, being measured over a small number of subjects, n, across a number of
experimental conditions, for example cancer versus non-cancer. Traditional genomics
studies such as individual gene analysis (IGA) often focus on a gene by gene analysis;
attempting to relate single genes to phenotype. There are considerations to take into
account with such an approach, such as multiple hypothesis testing issues and reliability
and interpretation of results Subramanian et al. (2005). It is often unpractical, if not
impossible to overcome such problems, hence the need for new approaches to relate gene
expression to phenotype.
It is well known and accepted that genes and hence proteins function in concert to
affect phenotype. Analyzing functionally dependent sets of genes rather than single
genes not only allows the experimenter an immediate interpretation to any positive re-
sults, but results from such analyses are generally more robust, Mootha et al. (2003),
Efron and Tibshirani (2006). These functionally dependent groups of genes, known as
gene sets, are defined on the basis of prior biological study, such as location on the chro-
mosome, and there are several freely available databases defining gene sets, for example
http://www.broadinstitute.org/gsea/msigdb/index.jsp.
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The general theme of methodologies for the analysis of sets of genes is as follows:
• Begin with some pre-defined gene sets;
• Determine some measure of gene effect within gene set;
• Summarize individual within gene set gene effects with some measure encompass-
ing information from these gene effects;
• Determine a p-value for evidence against a null hypothesis of no effect. Alterna-
tively determine a posterior probability of activeness of gene set.
There are many existing methodologies that are used for the analysis of gene sets such
as Subramanian et al. (2005); Efron and Tibshirani (2006); Jiang and Gentleman (2007);
Bauer et al. (2010); Isci et al. (2011); Shahbaba et al. (2011) and Stingo et al. (2011)
amongst others. Nam and Kim (2008) present a useful literature review on many of the
existing frequentist approaches to the analysis of gene sets alongside a rather limited sim-
ulation study, whilst Hung et al. (2012) provide a thorough description and investigation
of GSEA.
This thesis focuses on the methods of GSEA, GSA and BGSA. GSEA brought gene
set analysis methods to the forefront and was chosen as it is the most widely cited gene
set analysis method to date. One such paper citing GSEA is that by Efron and Tibshirani
(2006), who generalize the GSEA framework and introduce a new methodology for the
analysis of gene sets that is developed under this general framework, coined GSA. Finally,
BGSA was chosen for two reasons, firstly as it represents some of the latest methodology;
first published in 2011. Secondly BGSA was chosen as it is one of the few available
Bayesian methodologies for the analysis of gene sets.
Publications for the three methods above report the results for the analysis of a gene
expression data set on 50 cancer cell lines across 4486 genes, whereby 33 of the cell lines
have a p53 mutation and the remaining 27 cell lines are wild type. This freely available
p53 data set has become somewhat of a benchmark for comparison when presenting new
methods or models for the analysis of sets of genes. The analyses of the p53 data set
presented in the three papers will be discussed in Chapter 7.
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This chapter proceeds to introduce and describe the methodologies of GSEA, GSA
and BGSA in chronological order. Section 2.5 goes on to discuss the relative merits and
possible problems with the above methods.
2.2 Gene set enrichment analysis (GSEA)
GSEA aims to determine whether the members of a pre-defined set of genes, s, is ran-
domly distributed across L - a list of genes ordered based upon their correlation with the
given outcome call it rg g = 1,2, . . . ,N - or predominantly found near the top or bottom
of the list, thus indicating a relationship between the gene set s and the outcome.
The process of GSEA is carried out as follows
• An Enrichment score (ES) is calculated, which will indicate if the genes in the set
s are found primarily near the top or the bottom of the ordered list L. The ES is
a normalized Kolmogorov-Smirnov statistic. Suppose we have the ordered list of
genes L, which contains N genes and we have a given gene set s, which contains ms
genes, then we evaluate the fraction of genes in s (‘hits’) weighted by the magnitude
their correlation and the fraction of genes not in s (‘misses’) present up to a given
position i in L
Phit(s, i) = ∑
g∈s,g≤i
|rg|p
∑g∈s |rg|p
Pmiss(s, i) = ∑
g/∈s,g≤i
1
N−ms (2.1)
where p is taken to be 1 in Subramanian et al. (2005) and p=0 in Mootha et al.
(2003). The ES is defined as the maximum deviation from zero of the cumulative
sum of Phit − Pmiss. This is essentially a two sample Kolmogorov-Smirnov test
statistic.
• The significance of the ES is then estimated by permuting the outcome and recal-
culating the ES for the new outcome many times. This provides a null distribution
for the ES, from which a p-value for the observed ES can be calculated.
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• The final step of GSEA is to adjust for multiple hypothesis testing. This is achieved
by first normalizing the ES for each gene set, thus accounting for the size of each
set ms. The normalized ES is known as the normalized enrichment score (NES).
The false discovery rate (FDR) (as described in Chapter 1) is then calculated for
each NES.
Subramanian et al. (2005) present results for GSEA on six real gene expression data
sets, the p53 data set being one of them. However, no simulation study is implemented.
Therefore, although we are presented with results from GSEA we have no indication to
the performance of the method in identifying significant pathways of known effect.
2.2.1 GSEA in practice
The website http://www.broadinstitute.org/gsea/ provides many freely available
resources to aid researchers in performing GSEA, along with tutorials, guides and data on
which to practice the method. There are several ways provided for the implementation of
GSEA. These are grouped under two main headings GSEA-P which refers to applications
using java and GSEA-R which refers to the application using R. They do essentially the
same thing using the same methods, each with differing amounts of freedom and control.
The GSEA software is distributed in four different ways:
• GSEA desktop application, which is a menu driven application that is relatively
straightforward to use;
• GSEA java jar file, which allows command line usage;
• GSEA java source code, which allows the user to incorporate GSEA straight into
their analysis;
• R-GSEA, which is an R code that can be incorporated straight into the analysis and
is relatively simple to change/ modify.
Each of these methods have their advantages over the others. In particular the desktop
application and the R code are very useful.The desktop application has several additional
features, such as:
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• Ability to choose gene sets from a gene set browser, connected to MSigDB;
• Easy to load data by menu;
• Produces a table which includes columns for ES, FDR and p-values along with
enrichment plots and annotated reports of enrichment results;
• ‘Leading edge analysis’ which allows the user, after performing GSEA, to select
top scoring gene sets and compare the genes within these sets that occur before the
maximum of the running ES (i.e. the genes in a gene set which gives the set its high
ES). The idea behind this is that it allows the user to group leading edge subsets and
thus categorize high scoring gene sets into biological pathways.
A downside of the desktop application, which is a feature of many menu driven applica-
tions, is its lack of flexibility. The R-code is more adaptable, but requires a good working
knowledge of R. As mentioned on the website the R-code was developed as a prototype
for the method and is now generally used by researchers wanting to adapt the method of
GSEA.
GSEA is presented as a useful method for identifying pathways and processes of
groups of genes, which at individual gene level would be difficult to identify and in-
terpret. It is an adequate tool for dealing with high dimensional data of this type, and with
the freely available software and information it is a relatively straightforward method for
researchers to use. However, we must consider the usefulness, limitations and possible
shortcomings of such an ad-hoc method:
• The use of the Kolmogorov-Smirnov statistic is not necessarily the best choice of
test statistic;
• The weighting of the Kolmogorov-Smirnov statistic is not justified. Therefore the
weighting used is not necessarily the best;
• The method for construction of the null distribution is not unique. There is therefore
room for investigation and perhaps improvement here;
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• There are some statistical concerns about the method of GSEA as indicated by
Damian and Gorfine (2004).
GSEA is a user friendly method that can allow the user to find real effects from groups
of genes. However, there are papers which express concern over the method Damian and
Gorfine (2004); Efron and Tibshirani (2006).
2.3 Gene Set analysis (GSA)
Efron and Tibshirani (2006) give a more general overview of the methodologies involved
in testing for relationships between groups of genes and some outcome. There are two
particular areas on which the paper focuses:
• The discussion and assessment of the use of different gene set summary statistics;
• The construction of the null distribution.
2.3.1 The gene set summary statistic
There are several methods in common use for summarizing the test statistics zs of a set of
genes. These are:
• Mean;
• Absolute mean;
• Running sum Kolmogorov-Smirnov statistic (as in GSEA);
• Maxmean.
The maxmean test statistic is introduced in Efron and Tibshirani (2006) and is obtained
as follows. Say we are interested in gene set s, for which we have the individual gene test
statistics zs = (z1,z2, . . . ,zms) then
S(zi) = (S+(zi),S−(zi)) i = 1,2, . . . ,ms (2.2)
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where
S+(zi) = max(zi,0) i = 1,2, . . . ,ms
S−(zi) = −min(zi,0) i = 1,2, . . . ,ms (2.3)
And the maxmean test statistic is then given by
Smax = max
(
S(+),S(−)
)
(2.4)
The maxmean test statistic is designed to detect large values in either or both negative and
positive directions and is shown by Efron and Tibshirani (2006) to be consistently more
reliable as a gene set summary statistics than the other methods mentioned above.
2.3.2 The null distribution and Restandardization
The other main theme of this paper is the construction of the null distribution for the
gene set summary statistics. Two methods for the construction of the null distribution are
discussed by Efron and Tibshirani (2006). These are Randomization and Permutation,
each of these sampling methods having its own associated advantages and disadvantages:
• Permutation model - Under the permutation model the null hypothesis Hperm is that
the n rows of the expression matrix for gene set s are independently and identically
distributed vectors.
– Advantages of the Permutation model: It keeps (approximately) the same cor-
relation structure as the original data.
– Disadvantages of the Permutation model: It does not take into account the
parameters of the whole distribution (meanz,sdz) and so can lack relevance.
• Randomization model - Under the randomization model the null hypothesis Hrand
is that the gene sets are chosen by a random selection of m genes.
– Advantages of the Randomization model: Operates conditionally on the full
set z = (z1,z2, . . . ,zN) of z values, i.e. the randomization model tests the null
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hypothesis that given z, the observed gene set summary statistic S(zs) from
gene set s is no different than if the gene set s were chosen by a random
selection of genes.
– Disadvantages of the Randomization model: The randomization model de-
stroys gene-wide correlations, on which these methods lend much power, also
it is the interest in this correlation structure that aided in the development of
pathway analysis methodologies.
The method of GSA combines the randomization and permutation techniques to form
a method named restandardization. This method takes advantage of the desirable proper-
ties of each of the two methods. Essentially restandardization uses permutation to create
the null distribution and then corrects the permutation values to take account of the real
observed scores (as would be used in the randomization). The method of restandardiza-
tion is as follows
• Obtain the observed N z-scores for each gene z = (z1,z2, . . . ,zN) and compute the
mean and standard deviation (mobs,sdobs).
• Compute the observed gene set summary statistic Sobs(zs).
• Permute the data n times and compute z-scores zperm and corresponding gene set
summary statistics Sperm(zs) for each gene and gene set in each permutation. Com-
pute the mean and standard deviation over all permuted z-values (mperm,sdperm).
• Compute the p-value for each gene set using standardized gene set summary statis-
tics by
ps =
∑ I
(
Sperm(zs)−mperm
sdperm
> Sobs(zs)−mobssdobs
)
n
(2.5)
Where I() is the indicator function.
This method of restandardization does not need to be applied to GSEA as the use of the
Kolmogorov-Smirnov statistic automatically fulfills the criteria met by restandardization.
The GSEA test compares the observed cumulative distribution of z-values in s with the
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cumulative distribution of all other z-values, thus including information from the whole
distribution.
Efron and Tibshirani (2006) present analyses of two real data sets, one being the p53
data. A simulation study was also conducted whereby 1000 N(0,1) gene expressions were
generated across 50 samples in each of 2 classes. Genes were assigned to gene sets where
each non-overlapping block of 20 genes comprised a gene set (this simulation model will
be discussed in detail in Chapter 3). Five different scenarios were looked at, these being:
• All 20 genes in set 1 are 0.2 units higher in class 2;
• The first 15 genes in set 1 are 0.3 units higher in class 2;
• The first 10 genes in set 1 are 0.4 units higher in class 2;
• The first 5 genes in set 1 are 0.6 units higher in class 2;
• The first 10 genes in set 1 are 0.4 units higher in class 2 and the remaining 10 genes
in set 1 are 0.4 units lower in class 2.
The GSA procedure performs well at identifying the active gene set in all five cases and
the maxmean statistic proves to have better performance than the mean, absolute mean,
GSEA or absolute GSEA in identifying the active set. However, the simulation procedure
presented is not entirely realistic, as will be discussed in Chapter 3, and therefore a more
thorough simulation study would be useful.
The R library GSA has been introduced by Efron and Tibshirani to implement gene
set analysis with restandardization using the gene set summary statistics maxmean, mean
and mean absolute z-scores.
2.4 Bayesian gene set analysis (BGSA)
Bayesian gene set analysis (BGSA) as proposed by Shahbaba et al. (2011) utilizes within
gene set hierarchical Bayesian models to asses the significance of pathways with regard to
phenotypes of two levels. This model offers a more practical, knowledge based approach
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to the analysis of gene sets, utilizing probability distributions to describe the various layers
and mechanisms within gene sets that act as pathways to phenotype.
2.4.1 The Model
A within gene set hierarchical model is defined as
ysgi = αsg+βsgxi+ εsgi g = 1,2, . . . ,ms i = 1,2, . . .n s = 1,2, . . . ,K
ε ∼ N(0,σ2sg) (2.6)
where ysgi denotes the ith observed expression of the gth gene in gene set s, xi the phe-
notype (binary) of the ith subject, αsg the mean expression of gene g in set s and βsg
the change in expression of gene g in set s between the two phenotypes. The underlying
theme to the identification of active gene sets in this method is in the posterior distribution
of βsg, or, more specifically it is the posterior distribution of the variance of βsg, τs that is
used as a measure of activeness of gene set. Note that τs is common to all effects within
gene set s. For example if in set s all effects are very near to zero, then τs will be small.
On the other hand, if in another set s there are some relatively large negative effects, some
relatively large positive effects and some zero effects then τs will be large, representing a
more active gene set.
2.4.2 Prior model Specification
The model uses the following prior distributions on its parameters
σ2sg|ξ ,η ∼ Inv−χ2(ξ ,η2)
αsg|γ ∼ N(0,γ2)
βsg ∼ N(0,τ2s )
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whereby non-informative priors are used for the hyperparameters ξ ,η and γ . The prior
of βsg has associated hyperprior τ2s with its own mixture prior, such that
τ2s ∼ (1−λ )F0+λF1
Where
F0 = Inv−χ2(ν ,φ20 ) and F1 = Inv−χ2(ν ,φ20 +φ21 ) (2.7)
Where F0 is the distribution of τ2s under the null hypothesis of no set effect and F1 the
distribution of τ2s under the alternative hypothesis of a set effect. This is facilitated by
a relatively small scale parameter φ20 for the null part of the distribution and a relatively
large scale parameter φ20 +φ
2
1 for the alternative.The parameters in this prior are assumed
φ20 ,φ
2
1 ∼ gamma(1,1)
ν ∼ gamma(1,1)
λ ∼ beta(a,b)
Shahbaba et al. (2011) comment that in their analyses a= b= 1, however, in practice only
a small number of gene sets would be expected to be significant and a more informative
prior such as beta(1,10) might be used. In order to allow for sampling for λ , a binary
latent variable vs is introduced whereby
vs ∼ Bernoulli(p)
such that
τ2s |vs,φ0,φ1 ∼ (1− vs)F0+ vsF1
It is the posterior expectation of vs given data D, E[vs|D] that allows the calculation of the
significance of a gene set. The p-value pˆ0 is given by
pˆ0 = 1−E[vs|D] (2.8)
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2.4.3 Posterior Sampling
The priors used in this model, as specified previously, are all conditionally conjugate other
than ν ,φ20 ,φ
2
1 . Therefore the Gibbs sampler is used to obtain posterior samples of the
parameters. Posteriors for ν , φ20 and φ
2
1 are sampled using single variable slice sampling
because the priors for ν , φ20 and φ
2
1 are not conditionally conjugate. All of the R code
for the implementation of this model is freely available at http://www.ics.uci.edu/
babaks/Homepage/Codes.html and is straightforward to implement on a given data set.
Alongside analyses of the p53 data set, a simulation study is implemented to asses
the performance of BGSA and to compare its performance with that of GSEA and GSA.
Strictly speaking, data are not simulated in the data simulation procedure presented by
Shahbaba et al. (2011). The data simulation procedure presented is as follows:
• Individual gene analysis (IGA) is performed on the full set of genes and the top 20
genes are identified;
• Genes from the p53 data set are randomly reallocated amongst the 522 gene sets
in the molecular signatures data base C1 curation of gene sets. Therefore gene set
should be found significant by chance only;
• Five gene sets from the molecular signatures data base C1 curation of gene sets are
randomly selected to be made active;
• The 20 selected genes are randomly allocated to these five sets such that there are
five active gene sets.
Following this procedure, three scenarios are studied:
1. Gene sets are assumed mutually exclusive i.e. each gene belongs to only one gene
set;
2. Only the top 20 genes are assumed mutually exclusive with regards to gene set,
whereas other genes can belong to more than one set;
3. All gene sets can share common genes (including the top 20).
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The Receiver operator characteristic (ROC) curve is used to asses the performance of
GSEA, GSA and BGSA in determining active gene sets from the three above scenarios.
The ROC curve is a great way to evaluate model performance as it allows for simultaneous
consideration of power and type 1 error rate without specifying an arbitrary cut off. In this
case the five gene sets selected as active are taken to be true positives and the remaining
gene sets are taken to be true negative. It is shown that BGSA out performs all other
methods on such simulated data, with a consistently larger area under the curve (AUC)
in all three cases. It can also be seen that in such situations GSA is consistently more
succesful in identifying active gene sets than GSEA with a larger AUC in every case.
2.5 Appraisal of the methods
The three methods presented previously are some of the more prominent methods for the
analysis of gene sets.
Looking into results presented by the three papers from analyses on the p53 data set,
it can be seen that the methods find common results. However, this gives little insight into
the accuracy, dependence or performance of the methods as the truth behind such results
is unknown. To this note, a thorough simulation study should be carried out, whereby
data are simulated such that the truth of the significance of pathways are known. The data
should be simulated such that each methods ability to identify an active gene set is tested
and the sensitivity of the method is revealed.
A notable feature of the work presented by Subramanian et al. (2005) is that the
methodology is based on the application of ad-hoc analytical methods with no under-
lying statistical model and little justification for the application of these ad-hoc analytical
methods. It is discussed and demonstrated by both Damian and Gorfine (2004) and Efron
and Tibshirani (2006) that there are some quite simple cases where GSEA can be shown
to fail.
To a lesser degree, it could also be said that GSA, as presented by Efron and Tibshi-
rani (2006) is based on the application of ad-hoc analytical methods with no underlying
statistical model. However, Efron and Tibshirani (2006) do give some justification to
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the analytical methods that are used by GSA and a thorough simulation study is imple-
mented, testing the methods presented and comparing GSA to GSEA using the maxmean
test statistic alongside other gene set summaries (mean, absolute mean). The maxmean
test statistic and GSA are shown to be consistently more reliable in identifying active
gene sets. It is mentioned by Shahbaba et al. (2011), however, that there are cases, such
as when there are both positive and negative gene effects within a gene set, where the
maxmean statistic fails to detect real gene set effects.
BGSA, as proposed by Shahbaba et al. (2011) is a fully Bayesian hierarchical mod-
elling approach to the analysis of gene sets. Again, a simulation study is presented, show-
ing that this model is more successful at identifying active gene sets than GSA and GSEA.
As mentioned in Section 2.4, the data in the simulation study presented by Shahbaba et al.
(2011) is not strictly simulated. In fact, real data are used, but reorganized such that genes
found to be significantly related to phenotype (by IGA) are put into gene sets selected
to be significant. This could be misleading in some ways as it has been discussed and
examples shown (Chapter 1) that IGA can be unreliable in identifying significant genes.
The simulation procedures presented by Efron and Tibshirani (2006) and Shahbaba
et al. (2011) both leave room for improvement. The conditioning in the simulation model
proposed by Efron and Tibshirani (2006), whereby differential gene expression is mod-
elled conditional on outcome, could possibly be reversed to represent a more realistic
situation, i.e. outcome to be simulated conditionally on expression. The fact that the data
used in the simulation study presented by Shahbaba et al. (2011) are real, essentially with
the columns shuffled according to an IGA could lead to too much noise and an unfair and
possibly misleading comparison of the methods. Both presented simulation studies agree
that generally GSEA is the more unreliable method, they also show that their proposed
method is the most successful in identifying active gene sets. A larger, more realistic
and impartial simulation study would be useful to show the relative merits of the three
methods. It would be useful to implement a more in depth analysis of the methods, in-
vestigating in which situations the three methods work well and which cases the methods
fail. From such an analysis adaptations to existing methods/models or new methods/-
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models could be defined that can deal with a more broad spectrum of problem. A more
knowledge based practical appraisal of the methods could also be made after a simulation
study.
All three of the described methods propose univariate analyses; GSEA and GSA use
some test statistic for each gene and BGSA uses a univariate regression model for each
of the genes, clearly the relationship between phenotype and gene is not univariate as is
a theme of this group of methodologies. However, it must be noted that both GSEA and
GSA operate conditionally on the full set of test statistics. Another argument against these
univariate analyses is the inability to account for other descriptive variables, for example
age, weight or smoking status.
Of more concern with these methods is the conditionality. The methods condition
gene expression on phenotype, i.e. data|outcome whereas the aim of this class of model is
to model the pathway to phenotype, i.e. to model outcome|data. The distinction between
the two ways of conditioning such modelling is an important one. In general, we are
attempting to relate how the expression of genes or groups of genes relate to outcome, or
in other words we are attempting to determine the pathway to phenotype. This implies
a causal relationship whereby phenotype depends on gene expression. Hence it makes
sense to model conditionally on expression, rather than the other way around as in GSEA,
GSA and BGSA. Clearly, there is room for the construction of multivariate models for
this problem, whereby phenotype is modelled conditional on gene expression.
The following Chapter assesses simulation procedures and provides an in depth sim-
ulation study presenting applications of GSEA, GSA and BGSA to simulated data.
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Chapter 3
Comparison of existing methodologies for
gene set analysis
3.1 Introduction
As discussed in Chapter 2 there is the need to compare and evaluate the performance of
the previously described methods in identifying significant pathways. Possible limitations
with existing methods have been discussed in Chapter 2, in papers proposing new meth-
ods, such as Efron and Tibshirani (2006) and Shahbaba et al. (2011) and in review papers,
for example Nam and Kim (2008) and Song and Black (2008) amongst others. Several of
these papers present simulation studies.
There are several papers gathering together ideas about the analysis of gene sets, for
example Irizarry et al. (2009) and Nam and Kim (2008) provide an extensive list of many
available methods. Some papers focus solely upon simulation studies contrasting and
comparing methods, for example Goeman and Buhlmann (2007) and Song and Black
(2008). Nam and Kim (2008) also present a simulation study comparing some number
of current methods for the analysis of gene sets based upon the null hypothesis that they
test. The simulation studies presented in these publications follow a very similar vein
to that presented by Efron and Tibshirani (2006), in that gene expression is simulated
conditionally on phenotype. This does not necessarily result in the most realistic data.
Song and Black (2008) take the simulation procedure one step further by adding a corre-
lation structure to their simulated gene expressions. However, there is still an issue of the
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conditionality in the data simulation procedure.
It would be beneficial to consolidate ideas of data simulation models in order to pro-
duce a simulation study that follows a consistent theme and such that data are as realistic
as possible. A wide range of gene set scenarios should be examined such that a good prac-
tical understanding of the methods discussed (GSEA, GSA and BGSA) can be obtained.
The papers presenting GSA (Efron and Tibshirani (2006)) and BGSA (Shahbaba et al.
(2011)) provide simulation studies comparing the three methods, yet these simulation
studies are fairly limited, as discussed in Chapter 2 and below. A larger, more realistic
and independent simulation study should be carried out.
This chapter proceeds as follows; Section 3.2 introduces and discusses the relative
merits and weaknesses of two data simulation models. Section 3.3 outlines the simulation
study that will be carried out, defining several scenarios. Section 3.3 also presents results
from applying GSEA, GSA and BGSA to the simulated data sets. Finally, Section 3.4
discusses the results obtained from the analyses.
3.2 Data Simulation
There are essentially two approaches to modelling gene effect.
1. Condition on phenotype and model the effect of expression given phenotype.
2. Condition on expression and model phenotype conditional on expression.
3.2.1 Approach 1
The first approach is that adopted by Efron and Tibshirani (2006), whereby data is gen-
erated on N genes across n samples, and the expression of the gth gene in set s in the ith
subject is given by
xsgi ∼ N(0,1)
This represents the general practice of gene expression studies where gene expression is
transformed such that it follows a standard normal distribution. The first n/2 samples are
then taken to be of phenotype 1 and the second n/2 samples are taken to be of phenotype
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2. Each consecutive, non-overlapping block of ms genes is considered to be a gene set.
A gene set is then made active by adding or subtracting some constant from a number
of genes within that gene set in a given phenotypic condition. Nam and Kim (2008) and
Shahbaba et al. (2011) amongst many others follow this data simulation procedure.
This simulation model conditions on outcome and therefore assumes a univariate re-
lationship between gene expression and outcome. This is somewhat of an over simplifi-
cation, and it is unreasonable to assume such relationships.
An interesting feature of this approach is that it means that the marginal distribution
of expressions of active genes is no longer normally distributed with mean zero and vari-
ance one. Assuming we desire the expression of all genes to follow this standard normal
distribution, it is useful to look at this in more depth. Say we have gene xg ∼ N(0,1)
which we desire to be active, where half of the values in xg correspond to y = 0 and half
of the values in xg correspond to y = 1. Then following Approach 1 a constant c = 2 is
added to xg when y = 1. Now, if we look at the conditional distributions of xg in the two
0
y=0, sigma=1
0 c
y=1, sigma=1
Figure 3.1: Conditional distribution of xg|y where a constant c = 2 is added to xg when y = 1.
Vertical line showing the mean of the distribution.
phenotypic conditions, y = 0 and y = 1, as shown in Figure 3.1, it can be seen that the
conditional distributions of xg|y = 0 and xg|y = 1 both follow a normal distribution with
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means of 0 and c respectively and have variance one.
However, if we look at the marginal distribution of xg, as shown in Figure 3.2 then
clearly x no longer follows a standard normal distribution. This can also be described by
−6 −4 −2 0 2 4 6
Figure 3.2: Marginal distribution of xg. Vertical line showing the mean of the distribution.
the conditional expectation and conditional variance theorems, where
E[X ] = E
[
E[X |Y ]] (3.1)
and
V [X ] =V
[
E[X |Y ]]+E[V [X |Y ]] (3.2)
then the expected value and the variance of x is given by
E[X ] =
c
2
V [X ] = 1+
c2
2
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So after the constant c is added to x, we have
f (x) =
1√
8pi
(e−x
2/2+ e−(x−2)
2/2)
Clearly, this is not a desirable property, and data resulting from such a simulation no
longer look like data from a typical genomics study. A partial solution to such problems
could be to re-standardize xg such that
x′g =
xg− c2√
1+ c
2
2
(3.3)
This produces a distribution with mean zero and variance one, which, unless c is large
will be close to a normal distribution.
Song and Black (2008) take this simulation procedure one step further by allowing for
a correlation structure in the data, simulating gene expression
xi ∼MV N(0,Σ)
where Σ is defined by pairwise (gene by gene) correlation and xi is the expression of genes
g= 1, . . . ,N in subject i, i= 1, . . .n. It seems odd to define a correlation structure for sim-
ulating data when a univariate relationship that conditions gene expression on phenotype
is assumed.
3.2.2 Approach 2
In this approach we model phenotype conditionally on gene expression. A logistic model
is assumed for the relationship between phenotype for the ith subject yi and gene expres-
sion xi, such that
P[yi = 1] =
1
1+ e−ηi
i = 1, . . . ,n (3.4)
where
ηi = xiβ i = 1, . . . ,n (3.5)
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Data are to be simulated whereby the expression of the g= 1, . . . ,N genes in the ith subject
follow a multivariate normal distribution, i.e.
xi ∼MV N(0,Σ), i = 1, . . . ,n
where Σ is an N×N matrix with all diagonal elements equal to 1, therefore all off-diagonal
elements define pairwise correlations between genes. This, again, reflects the general
practice in gene expression studies of standardizing the expression of all genes to follow
a standard normal distribution, however we can now also define a correlation structure.
Gene set can be simply defined as consecutive non-overlapping blocks of ms =N/K genes
whereby there are K gene sets in total with s denoting gene set (s = 1,2, . . . ,K). Gene set
effect for gene set s, can be denoted as zs and specified as
zs =
 0 No gene set effect1 Gene set effect (3.6)
Gene effect for the gth gene in gene set s, denoted βsg is specified in a similar way,
whereby
βsg|(zs = 1) =

−δ Negative gene effect
0 No gene effect
δ Positive Gene effect
(3.7)
and
βsg|(zs = 0) = 0 (3.8)
So if a gene set is simulated as inactive then all genes within that gene set are considered
inactive and if a gene set is simulated as active, some genes within that set will have
a relatively large effect in either a positive or a negative direction. Figure 3.3 shows a
conceptual diagram of the simulation of gene and gene set effects. This simulation of
gene effect size on a linear predictor for a logistic model reflects ideas that some genes
will have no effect on phenotype, whilst differential expression of some genes will have a
positive effect on phenotype and differential expression of other genes will have a negative
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Gene Set 1 (z=1) Gene Set 2 (z=0) Gene Set K (z=0)
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l l l l
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l l l l
l l l l
l l l l
l l l l
l l l l
l l l l
− Active gene set
 (z=1)
− Inactive gene set
 (z=0)
l l− Active gene − Inactive gene
Figure 3.3: Conceptual diagram of the simulation of gene and gene set effects.
effect on phenotype. This is represented by the effects δ and −δ . From these simulated
gene effects and gene expressions a binary outcome (or phenotype) for the ith subject
(i = 1,2, . . . ,n) is then given by
yi ∼ Bernoulli
(
1
1+ exp
(− xiβ )
)
This data simulation procedure results in a data set whereby there is some large number
(N) of genes with normally distributed expression levels that are partitioned into N/K
gene sets. Some specified number of genes have an effect of zero (zs = 0) on phenotype,
while some specified number of genes inside active gene sets (zs = 1) will have some
relatively large known effect. More importantly, however, is that this procedure results
in a data set where outcome is modelled conditional on expression. In contrast to data
resulting from Approach 1, the marginal distribution of xg is the same for an active gene
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and an inactive gene, i.e. as x has not been altered in any way, then x still follows a
standard normal distribution. Figure 3.4 shows the conditional densities of x|y = 0 and
0
y=0, sigma=1
0
y=1, sigma=1
Figure 3.4: Conditional distribution of x|y from proposed simulation procedure.
x|y = 1. As can be seen the conditional densities have different means, yet still follow a
normal distribution with variance one. It is the specification of the effects (β ) that take
the smaller values from x that translate to y = 0 and the larger values from x to y = 1.
When looking at cases where a single gene affects phenotype, as shown here, there is
a clear distinction between the conditional distributions of x. However, with increasing
numbers of uncorrelated active genes we see a dilution of effect as outcome is described
by several effects. If we were to look at plots as in Figure 3.4 where we have even as few as
five genes affecting phenotype then we would see very little difference in the conditional
distributions. This is described by Figure 3.5. As can be seen in Panel A, where there is
only one gene affecting y, there is a clear distinction between the conditional distribution
of x|y. This distinction is blurred somewhat when there are five genes affecting y, as
shown in the boxplot of one of these genes in Panel B. In Panel C, where there are 20
genes affecting phenotype, there is little visible evidence of a difference in the conditional
distributions of one of these genes. Due to the variation in outcome being caused by many
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factors, it can be difficult to attribute this variation or proportion of variation to single
explanatory variables. This presents a problem in the analysis of such data, which closely
mimics a realistic situation. For the reasons presented, the simulation model from the
second approach will be used in the following simulation study.
l
l
l
l
l
l
l
l
l
y=0 y=1 y=0 y=1 y=0 y=1
−
3
−
2
−
1
0
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3
A B C
Figure 3.5: Box plots of conditionals of an active gene. Panel A shows a situation when there is
only one active gene. Panel B shows conditionals of one gene when there are 5 active
genes. Panel C shows conditionals of one gene when there are 20 active genes.
Looking at equivalent situations where data are correlated, this dilution of effects is
not so evident and the larger the correlation the less the dilution of effect.
3.3 Simulation Study
Following a similar thread to the majority of published simulation studies in this area, the
simulation study begins by focusing upon scenarios where gene expression is assumed
independent of other genes. This is followed by carrying out a second study, which is not
so common, where correlation structures are defined.
The area under the curve (AUC) of the receiver operator characteristic (ROC) curve,
as described in Chapter 1, will be used to summarize the performance of each method in
identifying the active gene set. The set defined as active being true positive and a non-
active (or null) set from each analysis being true negative. The ROC curve allows for
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the simultaneous consideration of power and type 1 error rate. This is particularly useful
as each method defines its own cut off; GSA suggests a level of 0.05 or 0.01, BGSA a
level of 0.1 and GSEA uses a cut off on the FDR of 0.25. Not only does the use of the
AUC remove scale, but no definition of p-value/ q-value cut off is required which allows
us to asses the true performance of each method without the need to define or use some
arbitrarily cut off.
3.3.1 Uncorrelated data
Data are simulated according to Approach 2 for n = 100 subjects across N = 1000 genes,
where Σ= I and each consecutive non-overlapping block of ms = 50 genes constituting a
gene set. Twelve scenarios are defined by the number of active genes within an active set.
As discussed in the previous section, a gene is considered active when it has a non-zero
effect (β ) on phenotype. In each of the twelve scenarios outlined below gene effect will
range from 0.5 to 5, thus giving 10 ‘sub-scenarios’ to each scenario. Every simulated data
set will be analyzed using GSEA, GSA and BGSA. The scenarios are:
1. One gene in set 1 is active;
2. Two genes in set 1 are active with effects of the same size in the same direction;
3. Two genes in set 1 are active with one positive effect and one negative effect;
4. Four genes in set 1 are active with effects of the same size in the same direction;
5. Four genes in set 1 are active with two positive effects and two negative effects;
6. Five genes in set 1 are active all with effects of the same size in the same direction;
7. Ten genes in set 1 are active all with effects of the same size in the same direction;
8. Ten genes in set 1 are active with five positive effects and five negative effects. All
effects are of the same size;
9. Twenty genes in set 1 are active all with effects of the same size in the same direc-
tion;
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10. Twenty genes in set 1 are active with ten positive effects and ten negative effects.
All effects are of the same size;
11. Forty genes in set1 are active with all effects in the same direction;
12. Forty genes in set 1 are active with twenty positive effects and twenty negative
effects. All effects are of the same size.
The three methods of interest will be applied to the data resulting from these 120 situa-
tions. This analysis will be replicated 100 times with newly simulated data (according to
the same parameters) and the AUC calculated over each of these 100 replicates. Essen-
tially there will be 12000 sets of simulated expression data looked at.
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3.3.1.1 Results
Figures 3.6 to 3.17 show plots of the AUC for each of the twelve scenarios for increasing
gene effect (β ). There are several consistent themes that can be seen from the AUC plots
for the 12 scenarios:
• In every case it can be seen that with increasing effect size, the AUC also increases.
I.e. the bigger the effect size the better the methods are at identifying the set as
active;
• When we have effect sizes in both positive and negative directions the performance
of GSA and particularly GSEA suffers;
• BGSA consistently performs the best out of the three methods;
• GSEA generally shows inferior performance to GSA and BGSA;
• The AUC for GSEA, particularly in scenarios where there are both positive and
negative effects, shows much variability with increasing effect size, for example
see Figure 3.17.
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Figure 3.6: Plot of AUCs for increasing β in scenario 1. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.7: Plot of AUCs for increasing β in scenario 2. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
64
beta
AU
C
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Figure 3.8: Plot of AUCs for increasing β in scenario 3. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.9: Plot of AUCs for increasing β in scenario 4. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.10: Plot of AUCs for increasing β in scenario 5. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.11: Plot of AUCs for increasing β in scenario 6. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.12: Plot of AUCs for increasing β in scenario 7. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.13: Plot of AUCs for increasing β in scenario 8. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.14: Plot of AUCs for increasing β in scenario 9. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.15: Plot of AUCs for increasing β in scenario 10. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.16: Plot of AUCs for increasing β in scenario 11. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
73
beta
AU
C
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Figure 3.17: Plot of AUCs for increasing β in scenario 12. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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3.3.2 Correlated data
Again, data are simulated according to Approach 2 for n = 100 subjects across N = 1000
genes, with each consecutive non-overlapping block of ms = 50 genes constituting a gene
set.
Here, however, it is the construction of Σ or more specifically the effect that it has
upon the performance of the three methods that is of interest. For our K = 20 gene sets,
Σ will be defined,
Σ=

Σ1 0 0 0
0 Σ2 0 0
0 0 . . . 0
0 0 0 ΣK

such that there is no correlation between gene sets, yet within gene set s = 1, . . . ,K we
have
Σs =

1 ρ · · · ρ
ρ 1 · · · ρ
...
... . . .
...
ρ ρ · · · 1

i.e. we define within gene set pairwise correlations of ρ for all genes within the set.
Clearly this correlation structure is an over-simplification, yet it is as realistic as possi-
ble whilst keeping a simple structure that is easily controlled. By definition gene expres-
sion within a gene set will be correlated, regardless of whether the gene set is related to
phenotype. Although real data would possibly show correlations between gene sets, there
is no reason to define gene set to gene set correlation in this case and in doing so there are
many considerations, such as:
• How do we define gene set to gene set correlation whilst keeping full control and a
realistic correlation structure?
• What is the rationale behind the between gene set correlation structure?
• In defining a full correlation structure methods may fail to work at all due to the
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complexity of the data.
Ten scenarios are defined by numbers of active genes, size of gene effects and most inter-
estingly by correlation of gene expression. We define one gene set as active where:
1. Twenty genes within the set are active, with effects on the linear predictor for the
logistic model of 0.5;
2. Twenty genes within the set are active, with ten effects on the linear predictor for
the logistic model of 0.5 and ten effects of -0.5;
3. Twenty genes within the set are active, with effects on the linear predictor for the
logistic model of 1;
4. Twenty genes within the set are active, with ten effects on the linear predictor for
the logistic model of 1 and ten effects of -1;
5. Twenty genes within the set are active, with effects on the linear predictor for the
logistic model of 3;
6. All fifty genes within the set are active with effects on the linear predictor for the
logistic model of 0.5;
7. All fifty genes within the set are active with twenty five effects on the linear predic-
tor for the logistic model of 0.5 and twenty five effects of -0.5;
8. All fifty genes within the set are active with effects on the linear predictor for the
logistic model of 1;
9. All fifty genes within the set are active with twenty five effects on the linear predic-
tor for the logistic model of 1 and twenty five effects of -1;
10. All fifty genes within the set are active with effects on the linear predictor for the
logistic model of 3.
To form sub-scenarios we vary ρ 0(0.05)0.5. We therefore end up with 11× 10 = 110
different data simulation criteria. To each of these 110 data simulation criteria 100 data
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sets will be simulated and the three methods applied, such that for every sub-scenario we
have 100 repetitions of each method.
3.3.2.1 Results
Figures 3.18 to 3.23 show plots of the AUC for each of the ten scenarios for increasing
within gene set pairwise gene correlation (ρ). As can be seen in all ten scenarios the
performance of each method decreases with increasing pairwise correlation. In every
case the performance of BGSA is the best and that of GSEA is the worst. Similar to the
uncorrelated scenarios as illustrated in the previous section, the more active genes there
are in the set and the larger the gene effect is, the better the methods perform.
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Figure 3.18: Plot of AUCs for increasing ρ in scenario 1. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.19: Plot of AUCs for increasing ρ in scenario 2. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
79
correlation
AU
C
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Figure 3.20: Plot of AUCs for increasing ρ in scenario 3. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.21: Plot of AUCs for increasing ρ in scenario 4. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.22: Plot of AUCs for increasing ρ in scenario 5. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
82
correlation
AU
C
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Figure 3.23: Plot of AUCs for increasing ρ in scenario 6. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.24: Plot of AUCs for increasing ρ in scenario 7. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.25: Plot of AUCs for increasing ρ in scenario 8. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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Figure 3.26: Plot of AUCs for increasing ρ in scenario 9. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
86
correlation
AU
C
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Figure 3.27: Plot of AUCs for increasing ρ in scenario 10. GSA-Dotted curve, BGSA-Dot-dash
curve, GSEA-Dashed curve
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3.4 Discussion and Conclusions
The data simulation approach as introduced above (Approach 2) produces realistic data
whereby gene expression directly affects phenotype, where phenotype is modelled con-
ditionally on gene expression and can be influenced simultaneously by any number of
genes. The vast majority of published simulation studies use some close variant of Ap-
proach 1 as a data simulation procedure, such as Efron and Tibshirani (2006), Nam and
Kim (2008) and Song and Black (2008).
Song and Black (2008) bring a new level to simulation Approach 1 in adding a corre-
lation structure. However, in their simulation procedure it is only active gene sets that are
given a correlation structure, whilst null gene sets are assumed a collection of independent
samples. Approach 2 defines a correlation structure for all gene sets, regardless of gene
expression. This is because a gene set is constructed due to some functional relationship
between its member genes regardless of differential expression. It is therefore safe to
assume that the expression of the member genes would be correlated to some degree. It
could be argued as to why between gene set correlation structure is not also included, as it
is reasonable to believe that in real data there will be between gene set correlation. For the
purpose of the simulation study presented here this added level of complexity would not
add enough to the study and brings to bear the question of how to define such a complex
structure in a realistic manner.
Song and Black (2008) represent a realistic situation, whereby they measure the mean
expression and the variance matrix of real data, and from such simulate data according
to these measures. In future work it would be interesting to carry this out, but using
simulation Approach 2 such that we can also model phenotype rather than using fixed
values.
It can be seen that BGSA performs very well for scenarios where data is uncorrelated.
In general BGSA performs the best out of the three methods in identifying the active gene
set, with consistently higher AUCs than the other methods. Due to the construction of
the model, when there are both positive and negative gene effects within the active gene
set BGSA actually performs better than when all effects are in the same direction. This
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is because the model relies upon the variance of gene effects within the gene set to be a
measure of activeness of a gene set.
It can also be seen that GSEA shows the worst performance. In cases where there
are both positive and negative gene effects GSEA performs poorly, with little better than
random prediction of the active gene set. The simulation study as outlined in Section
3.3 clearly demonstrates that GSEA is not the most reliable method to use in real life
applications as it is likely to miss any gene sets that combine both up- and down-regulated
genes, which are common.
GSA performs well on uncorrelated data. However, to a lesser degree, the method
does show the same characteristic drop in performance when there are both positive and
negative gene effects as in the case of GSEA. Concerns with GSA’s tendency to demon-
strate such behavior are expressed by Shahbaba et al. (2011) and are clearly shown here.
However, GSA is still a method to be rated and with the computational cost of running
analyses being so low it is useful.
It could be argued, that in the case of uncorrelated data, BGSA is somewhat over-
sensitive and when there is only one active gene within a set, once the effect becomes
moderately large (β = 2) the set is identified every time. GSEA does seem to be some-
what better calibrated than BGSA and GSA whereby larger percentages of active genes
with larger effects within a set are needed before the set is judged significantly enriched.
This brings us to the argument of how an active gene set is defined. This is a difficult
question and answers must be somewhat fluid, one solution to the above question would
be to use probabilities rather than p-values. This would allow uncertainty about the above
question to be expressed within the measure of activeness of the gene set.
It can be seen that the three methods show a characteristic drop in performance as the
within gene-set pairwise correlation increases. This is because the three methods assume
that a gene set is a collection of independent samples from the entire list of genes. The
majority of biologically defined gene sets will be a collection of correlated genes, i.e. gene
sets will not be made up of a random collection of independent genes. This assumption
of independence boosts gene set scores when there is in fact a within gene set correlation
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structure. This will therefore increase the incidence of false positives, thus decreasing the
performance of the methods as gene-gene correlations increase.
As an illustration of the above remark, say that we have gene sets sk, k = 1,2,K, each
containing mk genes, where s1 is related to phenotype but s2, . . . ,sK are not. Further-
more say that genes within a gene set have pairwise correlations of ρ and that there is no
between gene set correlation.
GSEA ranks these genes by their effect upon phenotype (using t-test statistics) and
calculates a running sum statistic according to gene set membership. Permutation of class
label is used to generate an empirical null distribution and t-test statistics calculated for
each gene within each permutation. Due to correlation between genes the t-statistics from
a given gene set will be ranked closely together in the list. There will therefore be gene
sets with no effect on phenotype that have many t-statistics near the top of the list and will
therefore be judged enriched.
Similarly, GSA, which uses the maxmean statistic to detect enrichment within a gene
set also gives many false positive results when dealing with correlated data. If gene ex-
pression within a null set is highly correlated, then the t-test statistics will also be corre-
lated, and so instead of the case with uncorrelated data, where we may see the occasional
false positive result for a single gene, this will be exaggerated to the whole or the majority
of the gene set for correlated data. The maxmean statistic will therefore, in some cases,
be particularly high for some null gene sets which will lead to false positive results.
In their paper Efron and Tibshirani (2006) show GSA to be superior to GSEA in
detecting active gene sets on data simulated according to Approach 1 as described previ-
ously. Shahbaba et al. (2011) also show GSA to be superior to GSEA on their simulated
data (simulation described in Chapter 2) and show BGSA to be superior to both GSEA and
GSA on the same simulated data. The simulation study presented here covers many more
scenarios than presented in previous papers and simulated data represent more realistic
situations than those presented by Efron and Tibshirani (2006) due to the conditioning of
the phenotype on expression. The simulation study presented by Shahbaba et al. (2011)
uses real data and so the truth behind whether the genes are related to phenotype, and
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how, is unknown. The simulation study presented here clearly demonstrates when and
where the given methods work and when they fail.
All three of the methods studied determine whether a gene set is active due to some
arbitrary p-value or FDR cut-off. Their performance can be assessed independently of
these cut-offs using ROC curves and the AUC as a summary of the ROC. However, where
the aim is to identify groups of genes worthy of further investigation these cut-off based
methods are somewhat black and white. To say ‘this gene set is related to pathway’ or
‘this gene set is not related to pathway’ is a little too certain and a more fluid definition is
required.
A demonstrative example of this is in scenario 1 as can be seen in Section 3.3 where
there is one active gene in the gene set, once the effect gets larger than 2 then BGSA
perfectly classifies the gene set as active, whilst GSA and GSEA show reasonable success
in classifying the set as significant. Now, ignoring the argument that a gene set with
only one active gene should not be classed as active, the three methods investigated here-
particularly BGSA- would class this set as active in many instances. To put this set in the
same bracket, for example, as a set with 10 active genes is very misleading. However, if
we had a probability that this set were active, it is much more interpretable and useful.
In defining a fully Bayesian model for the analysis of gene sets posterior probabilities of
‘activeness’ of gene set could be determined, which would allow the investigator a means
of identifying which sets are worthy of further investigation with regards to how likely it
is that the set is related to phenotype. The univariate nature of the three methods is also
something that should be addressed. If a model were designed such that phenotype is
modelled conditionally on gene expression we would be able to discard the assumption of
independence, thus constructing a model that can take correlation structure into account.
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Chapter 4
A Bayesian/frequentist hybrid model: A
model comparison approach to Pathway
analysis
As discussed previously, many current methods for the analysis of sets of genes make use
of ad-hoc analytical methods. In the development of an original model it is useful to go
back to first principles in order to structure a model that makes practical sense.
Some problems with current methods have been highlighted in previous chapters here
and in several papers, such as Nam and Kim (2008), Goeman and Buhlmann (2007) and
Song and Black (2008). There seem to be three major drawbacks to the majority of gene
set analyses:
• Gene sets tend to be assumed a collection of independent genes, i.e. uncorrelated.
This results in a drop in performance of the majority of methods as within gene set
correlation increases;
• Many methods struggle to deal with both up- and down-regulated genes;
• The majority of methods assume a univariate relationship in many cases condition-
ing gene expression on phenotype, rather than phenotype on condition.
We are presented with the problem of identifying the presence of a relationship be-
tween a pre-defined set of genes and a dichotomous phenotype. Some gene sets will have
an effect upon phenotype and some will not. Within a gene set that has an effect upon phe-
notype there will be genes whose expression directly effects phenotype and some genes
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whose expression will not affect phenotype. By definition the expression of genes within
a curated gene set will be correlated to some degree, whether those genes are differentially
expressed or not.
A method should be developed that overcomes the above outlined problems and re-
lates to the biology behind the process of a pathway affect on phenotype. A possible way
of doing this would be to use a model comparison approach where we define models that
fit a gene set that has no effect on phenotype and models that fit a gene set that does have
an effect on phenotype. It would be useful to define two models, one of which would best
fit a gene set that has no effect upon phenotype and one which would best fit a gene set
that does have an effect upon phenotype. The adequacy of the fit of these models could
be quantified and from this the significance of a relationship could be estimated.
The proposed approach utilizes Bayesian model fitting to fit within gene set logistic
regression models. There will be two models, defined by their priors. These will be a null
model, where it is believed that there is no gene set effect, and an active model, where it is
believed that there will be some gene effect. A model is defined such that there is a slope
parameter for every gene within a gene set on a linear predictor for both logistic models.
The adequacy of the fit of these models can be quantified and compared, and from this a
frequentist style p-value computed.
Section 4.1 proceeds to introduce the model as mentioned above. For the Bayesian
modelling part of the procedure (to be outlined), the posterior distribution for the slope
parameters is intractable algebraically, hence Markov chain Monte Carlo methods must be
employed to obtain samples from the posterior distribution. Section 4.2 presents several
possible MCMC algorithms and discusses which algorithm is the most suitable by way of
computer simulations.
4.1 The Model
The following proceeds to introduce a model comparison approach to gene set analysis.
In order for a model comparison two models are defined:
1. Null model - Designed to best fit gene sets that have no effect on phenotype;
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2. Active model - Designed to best fit gene sets that have a relationship with pheno-
type.
Using MCMC techniques these two models are fitted to each gene set simultaneously. It
should be noted that we do not define a fully multivariate model, yet neither is a univariate
relationship assumed. A within gene set multivariate relationship is assumed.
Essentially there will be two stages to the modelling. The first stage will consist of
the fitting of two logistic regression models to each gene set, the null model whereby we
assume there is no gene set effect, and the active model whereby we assume that there
are some gene set effects. The second stage is a comparison of the two models. The null
and active models can be contrasted by comparing the fit of the models, large, consistent
differences indicating a gene set effect.
4.1.1 Stage one - Logistic regression modelling
As mentioned above two logistic models are to be defined, however both models will have
the same likelihood. Looking within gene set s, containing ms genes, the likelihood for
such a model is given by
f (x|β ) =
n
∏
i=1
piyii (1−pii)1−yi (4.1)
where
pii =
1
1+ exp{−ηi} (4.2)
and
ηi =
ms
∑
g=1
xigβsg (4.3)
where xig is the expression of the gth gene in gene set s for the ith subject and βsg is the
slope parameter for the gth gene in gene set s. The difference in the two models is defined
by their respective prior distributions, f (β ).
4.1.1.1 The null model
A prior distribution for the slopes, β , for a null logistic model should represent a situation
where the genes in the set have no effect on phenotype. It is unreasonable to suggest that
all slopes within a null gene set are identically zero, as there will be noise in expression
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measurements and some genes within an inactive gene set may have a small effect on
phenotype. However, it is reasonable to suggest that effects will be small and centered
about zero. Therefore a normal prior of the form
f (β ) =
1√
2piσ
exp
{
−β 2
2σ2
}
(4.4)
is used, where σ is small. This represents prior beliefs that for a gene set that has no
relationship with phenotype and the majority of gene effects will be close to zero.
4.1.1.2 The active model
Within a gene set that has a relationship with phenotype it would be expected that there
are a whole range of gene effects. There will be some genes that have no effect upon
phenotype and some that have relatively large effects upon phenotype, both in negative
and positive directions. The prior distribution for the slopes, β , for an active logistic
model should represent this. Therefore a prior of the form
f (β )=
1√
2pi
(
(1− p)
2σ1
exp
{−(β −µ)2
2σ21
}
+
p
σ2
exp
{
−β 2
2σ22
}
+
(1− p)
2σ1
exp
{−(β +µ)2
2σ21
})
(4.5)
is used. Figure 4.1 shows a conceptual picture of prior distribution for β for an active gene
set. As can be seen this allows for very small effects, as it is believed that within an active
pathway not all genes will be up- or down-regulated. The broad peaks in the extremes
represent the belief that the up- or down-regulation of certain genes will have a positive or
negative effect upon the linear predictor for the logistic model The posterior distribution
of β is intractable algebraically, hence MCMC techniques should be employed. Section
4.2 discusses possible MCMC samplers and algorithms.
4.1.2 Stage two - Model comparison
The second stage of modelling relies heavily upon measures of posterior deviance and so
it is useful to first define deviance. Deviance (D) can be used as a measure of model fit
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Figure 4.1: Conceptual picture of prior distribution for β ’s for an active gene set
and can be defined for the likelihood f (x|β ), as
D(β ) =−2log f (x|β ) (4.6)
where x are data and β are unknown parameters. The mean posterior deviance is often
used as a measure of fit for Bayesian models, where the mean posterior deviance D¯ is
given by
D¯ = E[D(β )] (4.7)
Both deviance and the mean posterior deviance are particularly straightforward quantities
to calculate within MCMC steps and provide an accurate measure of model fit.
The deviance from both the null model and the active model, call them Dnull and
Dactive, are calculated within each MCMC step. From these vectors of null and active
model deviances an empirical distribution of deviances can be calculated. Then a fre-
quentist style p-value can be calculated
ps = mean
(
I(Dnulls > D
active
s )
)
(4.8)
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where I() is the indicator function.
It could be argued that using the posterior deviance of a model is not necessarily the
best measure of model fit, as it does not take into account model complexity, and that
maybe the Deviance information criterion (DIC), the Akaike information criterion (AIC)
or the Bayesian information criterion (BIC) would be a more suitable measure. However,
the two models include the same number of parameters (the same as the number of genes
within the given set) and so a measure that takes account of model complexity is not
essential and using the deviance as a measure suffices.
Figure 4.2 shows a simplified diagram of the general modelling procedure within gene
set s, as outlined above.
Gene set s
↙ ↘
Fit Null model Fit Active model
↓ ↓
1. Update parameters→ Dnull 1. Update parameters→ Dactive
↓ ↓
2. Update parameters→Dnull 2. Update parameters→ Dactive
↓ ↓
...
...
n. Update parameters→ Dnull n. Update parameters→ Dactive
↘ ↙
p = mean
(
I{Dnull > Dactive}
)
Figure 4.2: Conceptual picture of calculation of significance of the relationship between gene set
s and phenotype
4.2 The algorithm
As mentioned above the posterior distribution for β is intractable algebraically and there-
fore variates will be sampled from the posterior distribution using MCMC methods. A
suitable MCMC algorithm should be designed, along with the use of an effective and
efficient proposal density. It should be investigated whether to update all parameters at
once, known as block updating, or singly, which is often referred to as single component
98
updating.
Two bespoke algorithms have been written, one using block updating the other using
single component updating. The following outlines the two algorithms.
A single component Metropolis-Hastings algorithm has been designed such that within
a gene set parameters are updated one-by-one, conditional on all other parameters. The
order of this one-by-one update is randomized to speed convergence and aid the mixing
of chains. The algorithm is as follows
Algorithm 4.1 Single parameter update
1. Say we are at iteration t of the algorithm. Randomly select the order of updating
(without replacement), say we want to update βg
2. Propose β propg from q(β propg |β t−1g ).
3. Calculate the acceptance probability
α(β t−1g ,β
prop
g ) = min
(
1,
f (x|β propg ,β−g) f (β propg )q(β t−1g |β propg )
f (x|β t−1g ,β−g) f (β t−1g )q(β propg |β t−1g )
)
(4.9)
where β−g denotes all parameters other than βg at the current stage of updating.
4. Sample u∼U(0,1), if u < α then set β tg = β propg else β tg = β t−1g
5. Run through all βg, g = 1,2, . . . ,ms
6. Iterate t
A standard Metropolis-Hastings algorithm to block update all parameters in the given
gene set has been designed. This can be seen in Algorithm 4.2.
There are many proposal distributions that could be used as part of these algorithms, as
many proposal distributions (subject to certain conditions) will ultimately deliver samples
from the target distribution, Gilks et al. (1996). However, proposal densities that give
rapid convergence to the stationary distribution and that allow the chain to mix well are
more difficult to come by. To this end several proposal densities will be discussed and
implemented as part of the above algorithms, in order to find the best MCMC sampler for
the task in hand.
We are presented with the problem that within a given gene set, β can come from
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Algorithm 4.2 Block update
1. Say we are at iteration t of the algorithm.
2. Propose β prop from q(β prop|β t−1)
3. Calculate the acceptance probability
α(β t−1,β prop) = min
(
1,
f (x|β prop) f (β prop)q(β t−1|β prop)
f (x|β t−1) f (β t−1)q(β prop|β t−1)
)
(4.10)
4. Sample u∼U(0,1), if u < α then set β t = β prop, else β t = β t−1
5. Iterate t
a tri-modal distribution, as shown in Figure 4.1. This means that a sampler could have
problems in determining each of the three modes, be these problems getting stuck in one
particular mode and therefore not converging correctly or not having enough coverage
and therefore underestimating extreme modes. Some proposal distributions that will be
considered here are described below.
1. Independence sampler
A proposal density of the form
q(βprop|β ) = N(0,τ2) (4.11)
could be used to sample β . This proposal density is considered as it is hypothesized
that many of the β ’s will be approximately zero. A relatively large value for τ
should be used such that large positive and negative values for β will be covered.
2. Simple random walk
A proposal density of the form
q(βprop|β ) = N(β ,τ2) (4.12)
could be used to sample β . A simple random walk is considered as all modes of the
target distribution can be covered relatively quickly.
100
3. Bi-modal Independence sampler
A proposal density of the form
q(βprop|β ) = qN(0,τ21 )+(1−q)N(0,τ22 ) 0 < q < 1 (4.13)
is considered. The reason for this proposal density is that it is believed that there
will be many β ’s that are approximately zero, therefore setting τ1 to some small
value we will be sampling points close to zero. There will also be large values of
β in both positive and negative directions, setting τ2 to some relatively large value,
there will be coverage for both large positive and negative β ’s.
4. Tri-modal independence sampler
q(βprop|β ) = 12(1−q)N(−υ ,τ
2
1 )+qN(0,τ
2
2 )+
1
2
(1−q)N(υ ,τ21 ) 0 < q < 1
(4.14)
A proposal density of this form is considered as it is an approximation of the pos-
terior distribution of β and therefore should allow the algorithm to explore the full
parameter space. To avoid low acceptance rates υ and τ1 should be chosen such that
q(·|·) is heavier tailed than the posterior distribution for β . This is because if the
proposal were not heavier tailed than the posterior and the chain was in the tail of
the posterior then pi(β |x)q(β prop|β ) will be larger than pi(β prop|x)q(β |β prop) thus
giving a low acceptance probability. Heavy tailed independence proposals help to
prevent long periods stuck in the tails, therefore help to speed up mixing.
5. Tri-modal random walk
A proposal density
q(βprop|β ) = 12(1−q)N(−υ ,τ
2
1 )+qN(β ,τ
2
2 )+
1
2
(1−q)N(υ ,τ21 ) 0 < q < 1
(4.15)
has been designed to allow for coverage of the whole parameter space with the fixed
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modes of the proposal, with a random walk to help speed up convergence. We define
υ and τ1 such that the posterior distribution is approximately covered, yet with q
relatively large such that candidates generally come from the random walk mode of
the proposal. The rationale behind such a proposal is as follows. We are updating
parameters from a tri modal distribution, this comes with the associated problems
of getting stuck in the wrong mode and slow mixing. The random walk part of
the proposal allows us to generally sample candidates conditionally on the previous
state of the chain and the fixed parts of the proposal allow for large jumps into any
area of the parameter space, thus giving the chains an opportunity to converge to
the correct mode quickly and stay there.
In order to identify the best algorithm with the best proposal distribution for the prob-
lem in hand a small simulation study will be implemented.
4.2.1 A simulation study
To decide upon the most appropriate MCMC algorithm and sampler both algorithms will
be applied, with each of the 5 proposal distributions, to a small data set simulated from the
prior for the active model. In order to judge the performance of the ten MCMC samplers
Gelman-Rubin statistics will be calculated, Gelman-Rubin-Brooks plots will be drawn,
trace and ACF plots will be produced and acceptance rates will be calculated. Gelman-
Rubin statistics and Gelman-Rubin-Brooks plots will be based upon five parallel chains
initiated from different starting points. Based upon the five indicators described above the
best MCMC sampler for this problem will be chosen.
4.2.1.1 Data
Data will be simulated according to the data simulation procedure as outlined in Chapter
3. Data will be simulated for 100 subjects for only one gene set containing 10 genes.
Gene effects will be directly sampled from the prior
f (β )=
1√
2pi
(
0.1
0.6
exp
{−(β −1)2
2×0.62
}
+
0.8
0.05
exp
{ −β 2
2×0.052
}
+
0.1
0.6
exp
{−(β +1)2
2×0.62
})
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and simplified, such that we have
β = (1,−1,0,0,0,0,0,0,0,0)t
For simplicity gene expression is simulated with no correlation structure
X ∼MV N(0, I)
and hence
yi ∼ Bernoulli
(
1
1+ exp(−xiβ )
)
this results in 52 subjects being of phenotype 1 and 48 subjects being of phenotype 2.
4.2.1.2 Results
The samplers described above have been implemented within the above described algo-
rithms. Table 4.1 shows the parameters used within the different samplers as part of the
different algorithms. These parameters were chosen on the basis of previous study and
familiarity with the algorithms. Notice that no independence proposals have been imple-
mented as part of the block updating algorithm. This is because acceptance rates for such
samplers are so low as to make the sampler useless. Acceptance rates are extremely low
because in independently block sampling proposals it is unlikely that a proposal will cover
all three modes of the parameter space in the correct position of the vector of parameters.
Proposal Algorithm q(β prop|β )
1 Single component N(0,1)
2 Single component N(β ,0.062)
3 Single component 45N(0,0.06
2)+ 15N(0,1.8
2)
4 Single component 13N(−1.5,1.752)+ 13N(0,0.052)+ 13N(1.5,1.752)
5 Single component 110N(−1.5,0.82)+ 45N(β ,0.052)+ 110(1− p)N(1.5,0.82)
2 Block N(β ,0.0252)
5 Block 110N(−1.5,0.72)+ 45N(β ,0.0252)+ 110N(1.5,0.72)
Table 4.1: Table showing proposal distributions as implemented within the two algorithms. Pro-
posal numbering refers to that where the proposal distributions are introduced.
Appendices A.1 to A.7 show tables of point estimates of potential scale reduction
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factor (Gelman-Rubin statistic), corresponding upper confidence limits and acceptance
rates alongside trace plots, acf plots and Gelman-Rubin-Brooks plots for the ten logistic
slope parameters.
It can be seen from trace plots, Gelman-Rubin-Brooks plots and Gelman-Rubin statis-
tics that in all cases chains converge. Appendices A.1 to A.5 show that there seems to be
a compromise between mixing for the zero parameters (β3, . . . ,β10) and the mixing for
the non-zero parameters (β1,β2) in the single component updating algorithm. Either the
zero parameters mix a little slowly and the non-zero parameters mix well or vice versa,
a particularly extreme case of this can be seen in Appendix C, however, generally this is
not a problem and a reasonable compromise can be found.
Looking at Appendices A.3 and A.4 it can be seen that the chains for the zero pa-
rameters, in particular β5,β6,β7,β8 and β10 tend to jump out to relatively extreme values,
instantly returning to the mode at zero. This behavior drags down or pulls up the mean
for these parameters drastically.
The block updating algorithm overestimates β5 in both cases, as can be seen in Ap-
pendices A.6 and A.7.
4.2.2 Discussion: Which algorithm to use
It can be immediately seen that independent block updating samplers should not be used.
The independent proposals, used as part of a block updating algorithm, give very low
acceptance rates. We are attempting to update parameters sampled from a tri-modal dis-
tribution, updating all parameters at once independent of their last state, clearly the larger
the number of parameters we wish to update the smaller the acceptance probability. These
samplers are therefore impractical to use in this case. It should be noted that acceptance
rates are so low as to make convergence near impossible in some reasonable number of
iterations.
Independent proposal distributions as used as part of the single component updat-
ing algorithm result in inconsistent and somewhat low acceptance rates, for example in
the case of the independence sampler the chains for the parameters with value zero mix
poorly, whereas the chains for non-zero parameters mix reasonably well. Gelman-Rubin
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statistics as presented in Appendices A.1, A.3 and A.4 indicate that chains resulting from
all three single component independent updating algorithms converge. However, looking
at trace plots as shown in these Appendices it can be seen that in several cases chains will
jump out to rather extreme values in either a positive or a negative direction returning to
its stationary distribution in the next move. There is also the problem that if there are any
parameters with very extreme stationary distributions, independent samplers will take a
long time to converge and would mix very slowly, if not miss these modes completely. A
random walk proposal would converge much more quickly and could explore any sample
space.
The two block updating random walk samplers work well, with acceptance rates of
0.1828 and 0.5139 for the tri-modal random walk sampler and the simple random walk
sampler respectively. Looking more closely, it can be seen that with the simple random
walk sampler all chains mix well (Appendix A.6), converging quickly to the stationary
distribution and exploring the full space. Gelman-Rubin statistics as shown in Appendix
A.6 indicate convergence, with point estimates consistently close to one. Similarly, chains
for the tri-modal random walk sampler mix reasonably well, if a little slowly, with con-
sistently low Gelman-Rubin statistics. One major disadvantage with these (or any) block
updating algorithms is that as the number of parameters increases, acceptance rates cor-
respondingly decrease. As discussed in previous chapters gene sets can be of varying size
from very small to very large, this could lead to mixing problems when block updating
large gene sets. These potential mixing problems for large gene sets could be countered
by splitting up gene sets into smaller blocks or by altering variances of proposal distri-
butions, however, this can only solve the problem to some degree. Splitting gene sets
into smaller blocks in some ways defeats the object of block-updating and in a real life
situation could lead to problems both practically and computationally. Altering variances
is also an impractical solution, as altering the proposal distribution gene-set by gene-set
would be time consuming and somewhat contrived.
The single component updating algorithm does not suffer from this problem, as it up-
dates parameters one by one. Looking first at the simple random walk sampler it can be
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seen that chains mix well for all of the parameters. Gelman-Rubin statistics are consis-
tently low, indicating convergence. Chains for the tri-modal random walk sampler mix
well and also have correspondingly low Gelman-Rubin statistics.
All things considered, we should not use independent samplers or the block-updating
algorithms. The best performing and most versatile samplers are the single component
updating algorithm with the simple random walk and tri-modal random walk. There is
not much between the two samplers, yet it is believed that the tri-modal sampler is more
versatile and slightly better performing. The tri-modal random walk single component
updating sampler will therefore be used in future development of this model.
4.3 Discussion
The above mentioned Bayesian/ frequentist hybrid model for the analysis of gene sets
takes into account the biological processes behind a pathway effect upon phenotype.
However, we are still working with frequentist p-values, and with this comes the asso-
ciated problems of where and how to define a p-value cut off. It would be preferable to
work with proper probabilities. There are few fully Bayesian methods for the analysis of
gene sets that provide probabilities for activeness of gene set with regard to pathway to
phenotype. The following Chapter introduces two such models.
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Chapter 5
Application of RJMCMC to a Bayesian
gene set analysis
To date the majority of methods/ models for the analysis of gene sets focus upon produc-
ing some frequentist p-value against some null hypothesis relating to no gene set effect,
the construction of the method defining the null hypothesis, of which there are several,
for example:
• Hcompetitive0 : The genes within gene set s are at most as often differentially expressed
as genes in scompliment ;
• Hsel f contained0 : No genes in gene set s are differentially expressed.
As discussed through Chapters 2,3 and 4 there are many associated problems with us-
ing frequentist methodologies that employ a cut-off on a p-value relating to some gene
set score to determine activeness/enrichment of a gene set. Bayesian gene set analysis
(BGSA) is a fully Bayesian model, yet a frequentist style p-value is computed as a sum-
mary of the relationship between gene set and phenotype, conforming to the general gene
set analysis method.
When using a method where we must state if a gene set is active based upon whether
an associated p-value is below some arbitrarily defined cut-off, we have the problem of
defining that cut-off. Nam and Kim (2008), amongst others discuss problems with IGA,
one of these problems being the use of cut-offs on p-values. Methods for gene set analysis
were designed to overcome these problems, but in the case of p-value cut-offs the problem
107
has simply been scaled down, rather than solved. Another drawback to be considered
when using a method that uses a cut-off on p-values is that we are limited to concluding
a gene set active or not which is a little black and white. It would be beneficial to use a
probability, whereby we could say ‘gene set s is related to phenotype with probability p’
rather than ‘gene set s is related to phenotype’ or ‘there is no evidence that gene set s is
related to phenotype’.
There is of course the difficulty of bridging the gap between fitting a model to calcu-
lating a probability relating to the fitted model that indicates the degree to which a gene set
is active. Chapter 4 demonstrates this with the hybrid model, whereby Bayesian models
are fitted but a frequentist style p-value calculated based upon the fit of the models.
A development of the hybrid model, as introduced in Chapter 4, would be to instead
of simultaneously fit two models and compare, allow for a reversible jump step between
the two models. In doing so the hybrid model of Chapter 4 is developed into a fully
Bayesian model utilizing Reversible jump Markov chain Monte Carlo (RJMCMC). In
such a framework we can define an active model and a null model as in Chapter 4 and
then allow the reversible jump moves to define a probability for activeness of set.
The above mentioned model can be seen to work well (Chapter 6) as it takes a multi-
variate modelling approach to all genes within a gene set, where phenotype is modelled
conditionally on gene expression. Within gene set correlation structure is also accounted
for due to the within gene set model. However, it is of interest how gene sets affect the
behavior of other gene sets in the pathway to phenotype and the impact that this has on
phenotype. This is implemented by a fully multivariate model where all genes within the
data set are accounted for in a logistic model. Using RJMCMC we can propose to discard
gene sets from the model, or include gene sets in the model conditionally on the state
of all other gene sets. This results in probabilities referring to a gene sets contribution
to phenotype for each gene set and allows the user a much more in-depth view of the
behavior exhibited by genes and gene sets
This chapter is set out as follows; Section 5.1 introduces reversible jump Markov chain
Monte Carlo (RJMCMC) and provides an illustrative example of the algorithm in prac-
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tice. Section 5.2 describes in detail the first of the above introduced models, Section 5.3
introduces and describes the second of the above introduced models, and finally Section
5.4 discusses the two models.
5.1 Reversible jump Markov chain Monte Carlo
(RJMCMC)
The most commonly considered MCMC algorithm moves around the parameter space
of a single model. The RJMCMC algorithm moves around the parameter space of a
collection of models, generally finite in number. These models can be nested or arbitrary.
The algorithm is a combination of the standard MCMC algorithm for a given model, with
an additional step which moves between the different models. Suppose that there are
k = 1,2, . . . ,K models, call them Mk, under consideration. Each of the Mk models have
unknown parameter vector of length nk, θ k ∈ Rnk .
The joint posterior distribution of (k,θ k), pi(k,θ k|x), given data x, is obtained by
multiplying the joint prior of (k,θ k), f (k,θ k) = f (θ k|k) f (k) by the likelihood L(x|k,θ k).
The joint posterior distribution is therefore given by
pi(k,θk|x) = f (θ k|k) f (k)L(x|k,θ k)∑k′∈K
∫
Rnk′ f (θ k′|k′) f (k′)L(x|k′,θ k′)dθ k′
(5.1)
The reversible jump algorithm takes the above joint posterior distribution as the target
of an MCMC sampler, where the states of the Markov chain are of the form (k,θ k).
The output from such an algorithm provides us with not only posterior distributions of
parameters from each individual model, but also posterior probabilities of each model
given data x. The general RJMCMC algorithm is defined by Algorithm 5.1
5.1.1 Implementation of RJMCMC
Suppose we are currently residing in state (k,θ k) in model Mk and we want to propose
a move to state (k′,θ k′) in model Mk′ , which is of a higher dimension such that nk′ > nk.
In order to match dimensions between the model states the random vector of auxiliary
variables u of length dkk′ = nk′ − nk is generated from a known density qdkk′ (u). The
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Algorithm 5.1 Simplified RJMCMC algorithm
1 At t = 1 initialize k and θ k
2 At iteration t
2.1 Say we are currently residing in model k. Update the model parameters θ k.
2.2 Update model indicator k and corresponding parameters θ k
3 Iterate t.
current state θk and the auxiliary variables u are then mapped to the new state θ k′ by a
one-to-one mapping function gkk′(θ k,u). The acceptance probability of such a move is
given by
α[(k,θ k),(k′,θ k′)] = min
{
1,
pi(k′,θ k′|x)q(k′,k)
pi(k,θk|x)q(k,k′)qdkk′ (u)
∣∣∣∣∂gkk′(θ k,u)∂ (θ k,u)
∣∣∣∣} (5.2)
where q(k′,k) denotes the probability of proposing a move from model Mk to model Mk′
and
J =
∣∣∣∣∂gkk′(θ k,u)∂ (θ k,u)
∣∣∣∣ (5.3)
is the determinant of the Jacobian matrix. This term is required due to the change of
variables function gkk′ . The reverse move proposal, from model Mk′ to model Mk is made
deterministically and is accepted with probability
α[(k′,θ k′),(k,θ k)] = α[(k,θ k),(k′,θ k′)]−1 (5.4)
Note that as with standard MCMC a normalization constant is not needed to evaluate
α[(k,θ k),(k′,θ k′)].
5.1.2 A simple example
The survival times in years of 20 patients following major surgery are
0.8 8.8 1.4 3.8 6.7 0.8 0.3 2.1 3.7 1.2
2.7 2.7 4.5 1.5 10.1 1.4 10.3 1.2 8.7 5.3
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Two models are proposed for the distribution of the lifetime X of these patients.
• Model 1 (M1): X ∼ Gamma(α,β )
• Model 2 (M1): X ∼Weibull(γ,δ )
The one to one mapping between the parameters from Model 1 to Model 2 can be defined
as
γ =
1
α
δ =
1
β
and hence the Jacobian for the transformation J is
J =
1
α2β 2
There are many one-to-one mappings to choose from, yet a mapping should be chosen
such that
• Transformation of variables is straightforward.
• The Jacobian can be (relatively) easily calculated.
• The mapping allows for good mixing between models.
The above chosen bijection conforms to such criteria.
A RJMCMC algorithm has been written and implemented to fit the above models.
The following presents a small investigation into the behavior of this algorithm as applied
to the above data.
After a burn-in of 1000 iterations, 10,000 iterations were saved. Table 5.1 shows the
posterior means and variances of the parameters α,β ,δ , and γ . Figure 5.1 shows the trace
Parameter Mean Variance
α 1.6090 0.1790
β 0.4284 0.0171
δ 1.2166 0.0434
γ 4.4031 0.6918
Table 5.1: Posterior means and variances of parameters from the two models
plot of the reversible jump move between the two models. As can be seen the reversible
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Figure 5.1: Trace plot of the reversible jump between Models 1 and 2
jump moves between the two parameter spaces very often, with P[M1] = 0.12604 and
P[M2] = 0.87396 so clearly Model 2 is a more adequate fit for the data.
As a matter of interest and to aid in the understanding of the behavior of the reversible
jump algorithm, the above modelling will be repeated twice. The first repetition will
be implemented on a data set (data set 2) containing 100 measurements rather than 20,
whereby each measurement in the existing data is replicated five times. The second repe-
tition will be implemented on a data set (data set 3) containing 200 measurements rather
than 20, whereby each measurement in the existing data is replicated ten times. Figure
5.2 shows the trace plot of the reversible jump move between the two models for data set
2. As can be seen, with more data and therefore more support for Model 2 the algorithm
makes far fewer jumps between the models. The posterior probabilities of the two models
are P[M1] = 0.21166 and P[M2] = 0.78834
Figure 5.3 shows the trace plot of the reversible jump move between the two models
for data set 3. As can be seen, with again, more data the algorithm makes even fewer
jumps between the models. The posterior probabilities of the two models are P[M1] =
0.17094 and P[M2] = 0.82906
These examples show that with more data the algorithm makes far fewer jumps be-
tween the two models due to the added support for the models by the extra data, however,
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Figure 5.2: Trace plot of the reversible jump between Models 1 and 2 for data set 2
in this case, the posterior probabilities for the models are similar in all three cases. Re-
peated modelling of data 3 shows a lack of convergence, with widely varying results for
the model jumping move. This is due to such low acceptance rates and a much greater
number of iterations would be required to reach convergence. This tendency to ‘get stuck’
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Figure 5.3: Trace plot of the reversible jump between Models 1 and 2 for data set 3
in a parameter space when there is much support for a model is common to many RJM-
CMC problems, and it is not good to have such a low acceptance rate of model switching
moves. Rather than running an algorithm for a very large number of iterations, it would
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be more efficient to improve the mixing of the reversible jump and therefore speed up
convergence. A common technique used to improve acceptance rates of model switching
moves when there is a simple bijection, as in this case, is to add a zero mean random
variable to current parameters when proposing a model switching move. For example,
say we have two parameter vectors of the same length θ 1 and θ 2 corresponding to two
models. Then when proposing a move from model 1 to model 2 we propose θ 2 = θ 1+ξ ,
where ξ is a zero mean random variable. The variance of ξ can be calibrated to allow for
a reasonable acceptance rate of model switching moves. There is no such simple method
for variable dimensional problems, however, there are many recognized techniques to im-
prove the acceptance rate of model switching moves in variable dimension problems such
as those presented by Brooks et al. (2003) and Al-Awadhi et al. (2004).
5.2 The application of RJMCMC in a Bayesian analysis
of gene sets (BAGS)
The proposed approach to pathway analysis, Bayesian Analysis of Gene Sets (BAGS),
utilizes RJMCMC techniques in order to produce posterior probabilities of ‘activeness’ of
gene set. This approach enables the implementer to define active/ inactive gene sets with
respect to gene effect on phenotype within gene set. Essentially we define two models; a
null model for a null or inactive gene set and an active model, for a gene set that is active
in the pathway to phenotype. RJMCMC is then used to jump between the parameter
spaces of the two models. The posterior probability for the active model can then be used
as a probability of activeness of the gene set.
The null and active within gene set logistic models are defined as in Chapter 4 whereby
we define two logistic regression models by their priors.
5.2.1 A logistic regression model
As mentioned above two logistic models are to be defined, however both models will have
the same likelihood. Looking within gene set s, containing ms genes, the likelihood for
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such a model is given by
f (x|β ) =
n
∏
i=1
piyii (1−pii)1−yi (5.5)
where
pii =
1
1+ exp{−ηi} (5.6)
and
ηi =
ms
∑
g=1
xigβsg (5.7)
where xig is the expression of the gth gene in gene set s for the ith subject and βsg is the
slope parameter for the gth gene in gene set s. The difference in the two models is defined
by their respective prior distributions, f (β ).
5.2.1.1 The null model
A prior distribution for the slopes, β s, for a null logistic model should represent a situation
where the genes in the set have no effect on phenotype. It is unreasonable to suggest that
all slopes within a null gene set are identically zero, as there will be noise in expression
measurements and some genes within an inactive gene set may have a small effect on
phenotype. However, it is reasonable to suggest that effects will be small and centered
about zero. Therefore a normal prior of the form
f (β s) =
1√
2piσ
exp
{
−β 2s
2σ2
}
(5.8)
is used, where σ is small. This represents prior beliefs that for a gene set that has no
relationship with phenotype and the majority of gene effects will be close to zero.
5.2.1.2 The active model
Within a gene set that has a relationship with phenotype it would be expected that there
are a whole range of gene effects. There will be some genes that have no effect upon
phenotype and some that have relatively large effects upon phenotype, both in negative
and positive directions. The prior distribution for the slopes, β s, for an active logistic
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model should represent this. Therefore a prior of the form
f (β s)=
1√
2pi
(
(1− p)
2σ1
exp
{−(β s−µ)2
2σ21
}
+
p
σ2
exp
{
−β 2s
2σ22
}
+
(1− p)
2σ1
exp
{−(β s+µ)2
2σ21
})
(5.9)
is used, where 0 < p < 1 is a fixed value that is specified by the user. This allows for both
very small effects and large effects, as it is believed that within an active pathway not all
genes will be up- or down-regulated, the broad peaks in the extremes represent the belief
that the up- or down-regulation of certain genes will have a positive or negative effect
upon the linear predictor for the logistic model.
We put these models in a reversible jump MCMC framework, whereby not only do we
propose new parameters (β ) for a model and accept with probability α(β ,β prop) but we
also propose to move from the null model (M1) to the active model (M2) with probability
α(M1,M2) and vice versa.
The algorithm is outlined by Algorithm 5.2, note that as gene sets are considered
independent in the above model, steps 3 and 4 are interchangeable.
Before any application to real data, or subjecting the model to extensive simulation
study, it is necessary to observe the behaviour of the model on simulated data and to
calibrate proposal distributions in this new setting.
The above described model has been programmed in R and applied to a simulated data
set which has been simulated according to approach 2 in Chapter 3 complying to criteria
set out by scenario 7, whereby we have ten active genes with effects of 1 within one active
set, all other sets being inactive and ρ = 0. The model has been run for 10,000 iterations
after a burn in of 1000. Figure 5.4 shows trace plots of the model indicator for an active
set and an inactive set.
This results in posterior model probabilities for the active set of P[active] = 0.999 and
P[active] = 0 for the null set. As can be seen in Figure 5.4, mixing between models is
very poor and needs to be improved in order for the full model space to be explored. One
recognized technique for improving the mixing of reversible jump moves between models
of equal dimension is to add a vector of zero mean random variables to the parameter
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Algorithm 5.2 RJMCMC algorithm for gene set analysis
1 Say we are modelling gene set s, containing g = 1, . . . ,ms genes. Also say we are
in model Mm, m = (1,2), with parameters β at iteration t. Using a random order,
single component Metropolis-Hastings move, a within model parameter update is
made, according to Algorithm 4.2 in Chapter 4.
2 Propose to move from model Mm with parameters β to model Mmc , where Mmc
denotes the compliment of Mm, with parameters β ′. More generally, we could
have > 2 models and would have to include some model proposal scheme to the
algorithm, and add a model proposal density term to the acceptance probability (as
shown below). However, in this case such is not needed as if we have only two
models then if we are in model Mm then with probability 1 we propose to move to
model Mmc and vice-versa.
2.1 We must first define a one-to-one mapping between β s and β
′
s. This can be
done simply in this case, due to the fact that for every βg (g= 1, . . . ,ms) in Mm
there is an equivalent βg in Mmc . We therefore define the one-to-one mapping
as
β ′s = β s (5.10)
2.2 Calculate the acceptance probability for the move from Mm to Mmc
αmmc(β s,β
′
s) = min
{
1,
pimc(β ′s|x)
pim(β s|x)
}
= min
{
1,
f (β ′s)
f (β s)
}
(5.11)
as with the above mapping the likelihood is the same for both the numerator
and the denominator.
2.3 Sample u∼U(0,1), if u < α then move to Mmc with parameters β ′s else stay
in Mm with parameters β s.
3 Increment t.
4 Move through all s = 1, . . . ,K gene sets.
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Figure 5.4: Trace plot of the reversible jump between null and active models for simulated data.
Top: active gene set. Bottom: null gene set.
vector when proposing a model move, i.e. when moving from model Mm with parameters
β to model Mmc propose new parameters
β ′ = β +ξ (5.12)
where ξ is a zero mean random variable. Clearly, the likelihoods of the two models will
no longer cancel and so the posterior distributions for both models should be used in the
model move acceptance probability. This has been integrated into the above algorithm
whereby we set
β ′ = β +N(0,σ2mix) (5.13)
On running the algorithm and systematically exploring values for σ2mix it is found that
the best σmix = 0.0675. This altered algorithm has been applied to the above referred to
simulated data set. Figure 5.5 shows trace plots of the model indicator corresponding to
those shown in Figure 5.4.
As can be seen we now move around the parameter space much more freely, this
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Figure 5.5: Trace plot of the reversible jump between null and active models for simulated data.
Top: active gene set. Bottom: null gene set.
results in the much more realistic posterior model probabilities of P[active] = 0.6924 for
the active set and P[active] = 0.2377 for the null set.
In fitting such a model, not only do we produce posterior probabilities of activeness
of gene set, but we also have posterior samples for each of the gene effects on a linear
predictor for a logistic model on phenotype. Typically in a gene set analysis, once per gene
set p-values are calculated and gene sets of interest (with p-values below an arbitrary cut-
off) are selected, further analysis takes place whereby gene by gene statistics are looked
at, or some modelling procedure is implemented on genes from these gene sets of interest
to find the most contributing genes. In the case of the above outlined model, when fitted,
gene sets will have an associated probability of activeness and genes of interest within
these sets can be found by simple summaries of the posterior samples of the genes, for
example plotting histograms, and calculating means and variances of the parameters.
It could be questioned as to why multi-level models have not been used. For example,
hyperpriors could be put on the means and variances for the outlying normal distributions
in the active model. Consider adding such complexity to the active model, and fitting this
to a null gene set. Both the means and variances of the outlying normal distributions will
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shrink towards zero and the active model will become near identical to the null model,
hence rendering the reversible jump step useless. This would defeat the reasoning be-
hind such a procedure, where we rely on the reversible jump step between the models to
determine a probability for activeness of gene set.
The above outlined proposed model brings to bear many of the suggested improve-
ments to existing methodologies, whereby phenotype is modelled conditionally on gene
expression and within a gene set the expression of all genes is taken into account at once,
thus accounting for correlations between genes within gene set.
5.3 The application of RJMCMC to a Multivariate Bayesian
analysis of gene sets (MVBAGS)
In this approach to gene set analysis a fully multivariate approach is proposed, Multi-
variate Bayesian Analysis of Gene Sets (MVBAGS), whereby we allow for a variable
dimension logistic regression model for the full compliment of genes within a dataset.
The contribution to phenotype of each gene set and hence gene is taken into account in
such a model, allowing for gene set to gene set interaction. This therefore takes into ac-
count inter-gene set correlation and dependence. This will provide a more rounded view
of the processes involved in the pathway to phenotype and will provide posterior prob-
abilities of activeness of gene set conditionally on the expression of other genes and the
behavior of other gene sets.
To begin with we simply fit a logistic regression model for all genes
ηi = xiβ (5.14)
where
P[yi = 1] =
1
1+ exp(−ηi) (5.15)
where xi is the expression of N genes in subject i, i= 1, . . . ,n and β are the effects of these
genes upon a linear predictor (η) for phenotype y. Making use of RJMCMC we propose,
conditionally on all other gene sets, to remove gene set s, s = 1, . . . ,K, or to update its
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parameters β s. This is carried out systematically running through all gene sets, gene set
by gene set for some large number of iterations. The following goes on to describe the
model in detail.
5.3.1 The model
As mentioned above a logistic model will be fitted to the full compliment of genes,
whereby the likelihood is given by
f (X |β ) =
n
∏
i=1
piyii (1−pii)1−yi (5.16)
where
pii =
1
1+ exp{−ηi} (5.17)
and
ηi = xiβ (5.18)
where xi is the expression of N genes in subject i, i = 1, . . . ,n and β are the effects of
these genes upon a linear predictor (η) for phenotype y. A prior of the form
f (β )=
1√
2pi
(
(1− p)
2σ1
exp
{−(β −µ)2
2σ21
}
+
p
σ2
exp
{
−β 2
2σ22
}
+
(1− p)
2σ1
exp
{−(β +µ)2
2σ21
})
(5.19)
is used, where 0 < p < 1. This allows for both very small effects and large effects, the
peaks in the extremes represent the belief that the up- or down-regulation of certain genes
will have a positive or negative effect upon the linear predictor for the logistic model and
the distribution centered about zero represents beliefs that there will be many genes with
no effect on phenotype. The posterior distribution for the set of parameters β is given by
f (β |x) = f (β ) f (x|β )∫
f (β ) f (x|β )dβ (5.20)
which is intractable algebraically. Therefore MCMC techniques will be employed to
obtain samples from the posterior distribution of β , this will be described in further detail
below.
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The parameter vector β is a vector of variable length. The model will start with the
full compliment of genes, i.e. the vector β will start at length N. We will then partition β
into gene sets (for now assuming that gene sets do not overlap) s = 1, . . . ,K. Say we are
looking at gene set s, let β s denote the subset of gene effects corresponding to the genes
within gene set s and let β−s denote all other parameters, then we proceed to propose to
either remove the parameters for gene set s, i.e. set β s = 0 and thus move into a new model
space where β = β−s, or update the parameters belonging to gene set s conditionally on
β s and β−s using a standard MCMC step. So, at any point during this procedure we can
either include or exclude a gene set from the model. This will result in a fully multivariate
logistic regression model for phenotype whereby all genes are accounted for and each
gene set has an associated probability for its relationship with phenotype. This will also
result in model probabilities where we can find the most likely model which will consist
of gene sets that have an effect on phenotype.
Clearly in such a modelling procedure, a bijection between parameters is not so simple
as in the model outlined in the previous section, as rather than moving between just two
models we will be moving about 2K possible models, where K is the total number of gene
sets. For each update of all N parameters there are 2K possible models and therefore many
possible lengths for β , we therefore need to define auxiliary variables u in each case such
that (β ,u) always has length N. Once again, this is relatively simple within the RJMCMC
step, say we remove parameters for β s then
us = β s (5.21)
and in the next update we update us to the same recipe as we would update β s. The
following goes on to describe the practical workings of the model by way of a simplified
algorithm. An algorithm for this a model is outlined in Algorithm 5.3.
From such a modelling procedure we have probabilities for a number of models each
containing some number of gene sets, probabilities for activeness of each gene set and
posterior samples from the full compliment of genes that both take into account effects
from other genes and gene sets. From this output and the use of some simple summaries
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Algorithm 5.3 RJMCMC algorithm for gene set analysis
1 Say we are at time t = 1. Update the full compliment of N gene effects β . From
here on β is of variable length, with maximum length N, minimum length 0.
2 Now for any t > 1, we systematically run through all gene sets for each iteration of
t, say we are now in gene set s. Let kts denote a model indicator for gene set s at
time t, where kts = 1 if the parameters corresponding to gene set s, β s, are included
in the model and kts = 0 if not.
2.1 If kts = 1 then β s is included in the model. Therefore propose to remove β s
with probability
α(β ,β−s) = min
{
1,
pi(β−s|x)
pi(β |x)
}
(5.22)
sample u∼U(0,1). If u < α then accept the move and set kt+1s = 0, β = β−s
and update auxiliary variables us according to Algorithm 4.1, else kt+1s = 1,
update β s according to Algorithm 4.1 and move to next set.
2.2 If kts = 0 then β s is not included in the model. Propose to include β s with
probability
α(β ,β prop) = min
{
1,
pi(β prop|x)
pi(β |x)q(us)
}
(5.23)
Where β prop = (β ,us). Sample u ∼U(0,1). If u < α then accept the move
and set kt+1s = 1 and set β = β
prop, else kt+1s = 0, update us according to
Algorithm 4.1 and move to next set.
3 Move through the full set of s = 1, . . . ,K gene sets.
4 Iterate t.
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such as means, variances and credible intervals and plots such as histograms we are pro-
vided with the information to make a detailed interpretation of the underlying biological
features of the data set. This interpretation can be based upon which gene sets have a re-
lationship with phenotype, the strength of the gene set’s relationship with phenotype and
the exact relationship that the gene set has with phenotype with regards to the expression
of the genes within the set. In contrast to the majority of other methods, all of the above
information provided is fully multivariate and it therefore takes into account correlations
between genes both within and between gene sets. It also conditions phenotype on gene
expression, which seems to be a somewhat overlooked feature in many of the current
existing methods for the analysis of gene sets.
Chapter 6 applies BAGS and MVBAGS to simulated data. Results from the simula-
tion study will be used to assess the performance of each of the proposed models and to
compare and contrast the relative strengths and weaknesses of the two proposed models
with not only the existing methods as described in Chapter 2 but also with each other.
Chapter 7 then goes on to apply BAGS to a real data set.
5.4 Discussion
The two introduced models (BAGS and MVBAGS) hold many advantages over the rec-
ognized field of methods and models for the analysis of gene sets to date. The models are
defined from a biological point of view, whereby distributions are used to represent how
gene expression affects a linear predictor on a dichotomous phenotype, in such a way that
phenotype is modelled conditionally on gene expression. The modelling of phenotype
conditionally on gene expression is a different approach to all of the methods or models
that have been studied, however, from a modelling point of view this makes more sense
as we are interested in the pathway to phenotype, i.e. how the behavior a gene set affects
phenotype.
BAGS allows for multivariate effects within a gene set. The use of such a model
takes into account all genes within the set simultaneously, thus taking into account within
gene set correlations. MVBAGS allows for a fully multivariate model, such that not only
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within gene set correlations are taken into account, but also between gene set correlations
are accounted for. The ability to simultaneously consider all genes, either within a gene
set or the full compliment of genes, is advantageous as it allows us to recognize active
gene sets when single gene effects are small, yet there is a concerted effect from all genes
within a set, or in the case of the second model, if several gene sets are working together
to affect phenotype.
Thirdly both models produce posterior probabilities of activeness of gene set, rather
than p-values against some null hypothesis. As mentioned previously this is advanta-
geous as it allows for a more fluid definition of activeness, and allows us to associate a
probability to our statement of activeness.
These models appear to have many advantages over the current methods for the anal-
ysis of gene sets. However, it would be very useful to determine how these models work
practically. The following chapter goes on to apply these methods to several sets of sim-
ulated data.
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Chapter 6
Some case studies based upon simulated
data
Chapter 5 presented two new Bayesian models for the analysis of gene sets. It is claimed
that the methods are superior to existing methods, the main advantages being
• Phenotype is modelled conditional on gene expression.
• Gene expression is modelled simultaneously either within a gene set or for the entire
set of genes.
• Posterior probabilities of activeness are computed, rather than p-values.
BAGS and MVBAGS are computationally intensive. Due to the time and computing
constraints of this project, it is unfeasible to implement a large scale simulation study.
Access to a powerful computer, or a lot of time for running repetitive simulations are
beyond the reach of this project and so several small case studies will be designed to
allow us to explore some of the properties of BAGS and MVBAGS and to allow for a
comparison with GSEA, GSA and BGSA.
The presented models make sense from both a biological and a statistical modelling
point of view. However, it must be checked not only that the proposed models work,
but how well they work, how they compare to one another and how they compare to the
existing methods discussed in Chapters 2 and 3. In applying the five methods to simu-
lated data whereby the truth of any effects within the data are known, we can fairly and
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independently judge the performance of the proposed methods compared to the existing
methods.
The remainder of this chapter is arranged as follows: Section 6.1 outlines the inves-
tigation and introduces the scenarios according to which data will be simulated. Section
6.2 presents results from applying GSEA, GSA, BGSA, BAGS and MVBAGS to the sim-
ulated data. Finally, Section 6.3 discusses results.
6.1 Outline
As mentioned above, the resources for computationally intensive, repetitive simulations
are not available. Due to this, a repetitive simulation study will not be implemented.
Eight data simulation scenarios will be defined, whereby GSEA, GSA, BGSA, BAGS
and MVBAGS will be applied to each of the resulting eight data sets. Data will be sim-
ulated according to Approach 2, as outlined in Chapter 3, whereby we simulate an n×N
matrix of gene expressions, X , where n = 100 is the number of subjects and N = 200 is
the number of genes. We define gene effects, β , due to the criteria laid out by our data
simulation scenarios. Phenotype, y, is simulated as a random binomial with probability
1/(1+exp(−Xβ )) and finally each non-overlapping block of 20 genes constitutes a gene
set, such that we have 10 gene sets.
The eight scenarios will therefore be defined by the following criteria:
• The number of active gene sets;
• The number of active genes within an active gene set;
• The size of the effect of the active genes within the active gene set(s) on the linear
predictor for phenotype;
• The pairwise correlation between genes within gene sets;
In defining data simulation scenarios we have the problem that there is an infinitely large
space of scenarios. We need to define some realistic scenarios that will reveal the be-
haviour of the five methods in different but realistic situations. As there is no hard and
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fast definition for an active gene set, we should look at some different ways in which a set
could be active and assess each method’s ability to detect these active sets. It would be
interesting to look at both small and large gene effects with differing numbers of active
genes, and with different correlation structures. It would also be of interest to observe the
performance of the five methods when there are several active gene sets. The following
defines eight data simulation criteria that attempts to cover these points.
The scenarios are defined such that we have situations where a single active gene set
with either small numbers of active genes within the active set having relatively large
effects, situations where we have many small gene effects and situations where there
are a middling number of active genes with middling effect sizes. There should also be
scenarios that look at a number of active sets. This is implemented where an active gene
set is defined to be the set with middling effects and repeated such that we have some
number > 1 of active gene sets within a data set. In each case data are simulated as above
with two different pairwise correlations for genes within gene set, these being ρ = 0 and
ρ = 0.25. Table 6.1 summarizes these data simulation criteria.
Scenario No of active sets Gene effects in active sets Correlation
1 1 β1 =−β2 = 3 0
2 1 β1 : β10 = 1 0
3 1 β1 : β10 =−(β11 : β20) = 0.5 0
4 3 β1 : β10 = 1 0
5 1 β1 =−β2 = 3 0.25
6 1 β1 : β10 = 1 0.25
7 1 β1 : β10 =−(β11 : β20) = 0.5 0.25
8 3 β1 : β10 = 1 0.25
Table 6.1: Simulation criteria for the eight data scenarios
In the next section we present results from the application of GSEA, GSA, BGSA,
BAGS and MVBAGS to the simulated data.
6.2 Results
The five methods of interest have been applied to the eight simulated data sets.
• GSEA is implemented with the recommended 1000 permutations.
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• GSA is implemented with the 200 recommended permutations.
• BGSA obtains posterior samples and bases its p-values upon a recommended 2000
iterations after a burn-in of 200.
• Probabilities from BAGS and MVBAGS are based upon 20,000 posterior samples
after a burn-in of 10,000
Figures 6.1 to 6.8 show bar charts of the results from scenarios 1 to 8. In the case of
GSA and BGSA the bars in the bar charts show p-values against their respective null
hypotheses. The bars for GSEA represent fdr q-values and in the case of the Bayesian
methods as presented in Chapter 5 the bars show 1−P[active] or in other words P[null].
It has been chosen to show 1−P[active] for ease of comparison with frequentist p-values
when presented on a bar chart. The horizontal lines in each of the plots show p-value
cut-offs corresponding to GSEA, GSA and BGSA depending upon the method. It is
recommended by Subramanian et al. (2005) when using GSEA to use a cut-off on the FDR
q-values of 0.25. Efron and Tibshirani (2006) define a p-value cut-off of 0.05 when using
GSA. Shahbaba et al. (2011) employ a cut-off of 0.1 in their paper presenting BGSA, this
will be used here. BAGS and MVBAGS produce probabilities of activeness of gene set
(shown below as 1−P[active]), there is therefore no strict cut-off, however, gene sets with
P[active]≥ 0.5 will generally be considered interesting.
Table 6.2 provides p-values, q-values and P[active] for the active gene sets in each of
the eight scenarios. The underlined values highlight where an active gene set has not been
identified by the given method.
As can be seen in Table 6.1 the data simulation criteria for Scenarios 1 and 5, Sce-
narios 2 and 6, Scenarios 3 and 7 and Scenarios 4 and 8 are identical, apart from the fact
that a correlation structure is defined for Scenarios 5, 6, 7 and 8. Comparing Scenarios 1
and 5 (Figures 6.1 and 6.5) it can be seen that with the addition of a correlation structure
the performance of GSEA, GSA and BGSA is worse, whereas BAGS and MVBAGS give
slightly higher probabilities of activeness. This can also be seen when comparing Scenar-
ios 3 and 7, results of which can be seen in Figures 6.3 and 6.7. Comparing results from
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Scenarios 4 and 8, no patterns can be seen moving from uncorrelated data to correlated
data. It would be interesting to repeat these analyses in a repetitive simulation study to
see exactly how this addition of a correlation structure affects results.
Active set(s) Method
identified GSEA GSA BGSA BAGS MVBAGS
Scenario 1 0.6826743 0.0700000 0.4389764 0.9502333 0.9997333
Scenario 2 0.0000000 0.0000000 0.1525789 0.9051000 0.9799000
Scenario 3 0.7706575 0.0100000 0.1689010 0.9118333 0.9991333
Scenario 4 0.0099000 0.0050000 0.4757358 0.7581000 0.7338333
0.0340071 0.0000000 0.3907052 0.9908667 0.9768000
0.2590949 0.0800000 0.4767546 0.8600000 0.7588000
Scenario 5 1.0000000 0.1350000 0.2118809 0.9994000 0.9997667
Scenario 6 0.0000000 0.0000000 0.1351847 0.9991000 0.9999333
Scenario 7 0.8549705 0.3000000 0.4248656 0.9921333 0.8064667
Scenario 8 0.0245833 0.0050000 0.1323388 0.9998333 0.9999667
0.1803993 0.0600000 0.1998703 0.8432667 0.9970667
0.2087529 0.0550000 0.1882647 0.9864000 0.9998667
Table 6.2: P-values,q-values and P[active] for active gene sets. P-values,q-values and P[active]
that miss a defined cut off are underlined.
BGSA consistently misses active gene sets as can be seen in Table 6.2, however, this
can clearly be seen to be down to the choice of cut-off in the majority of cases. It can be
seen that in the majority of scenarios the p-value is much smaller for active sets than for
inactive sets (this is not so for Scenarios 4 and 7). This is down to the rather complicated
construction of a frequentist style p-value from a Bayesian model, as discussed in Chapter
2. Either a more relaxed cut-off is needed, a slightly different interpretation of the p-value
should be made or the calculation of the p-value should be better calibrated. In a real
life situation where the truth behind which gene sets are active is unknown, the above
comments could not be made and therefore real effects could and would be missed. This
possible problem is not highlighted by the repetitive simulation study in Chapter 3 because
the AUC is used.
GSA performs reasonably in identifying the active sets, six out of twelve active sets
are not identified. GSA fails to identify the active sets in Scenarios 1 and 7, misses one of
the three active sets in Scenario 4 and fails to identify two of three active sets in Scenario
8. GSA provides several false positive results, in fact Scenarios 2, 4 and 5 are the only
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cases where GSA does not give at least one false positive.
GSEA fails to identify the active gene sets in Scenarios 1, 3, 5 and 7, fails to identify
one out of three active gene sets in Scenario 4 and fails to identify two out of three active
gene sets in Scenario 8. It should be noted that gene sets in Scenarios 1, 3, 5 and 7 are
active with gene effects in both a positive and a negative direction. GSEA gives several
false positives, these are in Scenarios 1, 3, 6, and 7. Interestingly, in the case of Scenario
1 the active gene set is missed by both GSEA and GSA, yet both methods classify gene
set 6 as active when in fact it is inactive.
BAGS can be seen to perform well in all cases. Every active gene set is identified
successfully. All inactive sets have P[active] < 0.5, the model therefore gives no false
positive results for the eight scenarios.
MVBAGS successfully identifies all active gene sets and there are no false positive
results.
To summarize the results from BAGS and MVBAGS it can be said that they both
appear successful in identifying active gene sets in a range of scenarios.
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Figure 6.1: Bar chart for Scenario 1 (1 active gene set; β1 = −β2 = 3; correlation=0). RJ1 de-
noting BAGS and RJ2 denoting MVBAGS. Vertical bars showing q-values for GSEA,
p-values for GSA and BGSA and 1−P[active] for BAGS and MVBAGS. Dashed hori-
zontal line showing a p-value cut-off of 0.05 for GSA, dot-dash line showing a p-value
cut-off of 0.1 for BGSA and dotted line showing an FDR cut-off for GSEA of 0.25.
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Figure 6.2: Bar chart for Scenario 2 (1 active set; β1 : β10 = 1; correlation=0). RJ1 denoting BAGS
and RJ2 denoting MVBAGS. Vertical bars showing q-values for GSEA, p-values for
GSA and BGSA and 1−P[active] for BAGS and MVBAGS. Dashed horizontal line
showing a p-value cut-off of 0.05 for GSA, dot-dash line showing a p-value cut-off of
0.1 for BGSA and dotted line showing the FDR cut-off for GSEA of 0.25.
p−
va
lu
e 
or
 1
−P
[ac
tiv
e
]
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
geneset 1 geneset 2 geneset 3 geneset 4 geneset 5 geneset 6 geneset 7 geneset 8 geneset 9 geneset 10
rj1 rj2 gs
a
bg
sa
gs
ea rj1 rj2 gs
a
bg
sa
gs
ea rj1 rj2 gs
a
bg
sa
gs
ea rj1 rj2 gs
a
bg
sa
gs
ea rj1 rj2 gs
a
bg
sa
gs
ea rj1 rj2 gs
a
bg
sa
gs
ea rj1 rj2 gs
a
bg
sa
gs
ea rj1 rj2 gs
a
bg
sa
gs
ea rj1 rj2 gs
a
bg
sa
gs
ea rj1 rj2 gs
a
bg
sa
gs
ea
Figure 6.3: Bar chart for Scenario 3 (1 active set; β1 : β10 = −(β11 : β20) = 0.5; correlation=0).
RJ1 denoting BAGS and RJ2 denoting MVBAGS. Vertical bars showing q-values for
GSEA, p-values for GSA and BGSA and 1− P[active] for BAGS and MVBAGS.
Dashed horizontal line showing a p-value cut-off of 0.05 for GSA, dot-dash line show-
ing a p-value cut-off of 0.1 for BGSA and dotted line showing the FDR cut-off for
GSEA of 0.25.
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Figure 6.4: Bar chart for Scenario 4 (3 active sets; β1 : β10 = 1; correlation=0). RJ1 denoting
BAGS and RJ2 denoting MVBAGS. Vertical bars showing q-values for GSEA, p-
values for GSA and BGSA and 1−P[active] for BAGS and MVBAGS. Dashed hori-
zontal line showing a p-value cut-off of 0.05 for GSA, dot-dash line showing a p-value
cut-off of 0.1 for BGSA and dotted line showing the FDR cut-off for GSEA of 0.25.
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Figure 6.5: Bar chart for Scenario 5 (1 active gene set; β1 =−β2 = 3; correlation=0.25). RJ1 de-
noting BAGS and RJ2 denoting MVBAGS. Vertical bars showing q-values for GSEA,
p-values for GSA and BGSA and 1−P[active] for BAGS and MVBAGS. Dashed hori-
zontal line showing a p-value cut-off of 0.05 for GSA, dot-dash line showing a p-value
cut-off of 0.1 for BGSA and dotted line showing the FDR cut-off for GSEA of 0.25.
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Figure 6.6: Bar chart for Scenario 6 (1 active set; β1 : β10 = 1; correlation=0.25). RJ1 denot-
ing BAGS and RJ2 denoting MVBAGS. Vertical bars showing q-values for GSEA,
p-values for GSA and BGSA and 1− P[active] for BAGS and MVBAGS. Dashed
horizontal line showing a p-value cut-off of 0.05 for GSA, dot-dash line showing a
p-value cut-off of 0.1 for BGSA and dotted line showing the FDR cut-off for GSEA
of 0.25.
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Figure 6.7: Bar chart for Scenario 7 (1 active set; β1 : β10 =−(β11 : β20) = 0.5; correlation=0.25).
RJ1 denoting BAGS and RJ2 denoting MVBAGS. Vertical bars showing q-values for
GSEA, p-values for GSA and BGSA and 1− P[active] for BAGS and MVBAGS.
Dashed horizontal line showing a p-value cut-off of 0.05 for GSA, dot-dash line show-
ing a p-value cut-off of 0.1 for BGSA and dotted line showing the FDR cut-off for
GSEA of 0.25.
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Figure 6.8: Bar chart for Scenario 8 (3 active sets; β1 : β10 = 1; correlation=0.25). RJ1 denot-
ing BAGS and RJ2 denoting MVBAGS. Vertical bars showing q-values for GSEA,
p-values for GSA and BGSA and 1− P[active] for BAGS and MVBAGS. Dashed
horizontal line showing a p-value cut-off of 0.05 for GSA, dot-dash line showing a
p-value cut-off of 0.1 for BGSA and dotted line showing the FDR cut-off for GSEA
of 0.25.
6.3 Discussion
The eight Scenarios presented above show a range of simplified possible situations that
may be encountered when performing a gene set analysis. It can be seen that BAGS and
MVBAGS perform better and more consistently than either GSEA, GSA or BGSA.
The problem of having a p-value cut-off has been highlighted in this chapter. It can be
seen that with the recommended p-value cut-off of 0.1 for BGSA many active sets would
be missed. However, ignoring the cut-off it can clearly be seen that BGSA does in fact
identify several of the active gene sets correctly. This is supported by findings in Chapter
3 where BGSA is proven to be more reliable at identifying more active gene sets than
GSEA or GSA, by using the AUC as a measure of performance. The AUC measures the
performance of a method across all cut-offs and so the 0.1 cut-off was not an issue there.
BAGS and MVBAGS cannot exhibit such problems as no cut-off is necessary.
The performance of GSEA and GSA is consistent with the findings in Chapter 3.
However, here GSEA performs a little better in identifying the active gene set than GSA.
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GSA also gives more false positive results than GSEA.
BAGS and MVBAGS can be seen to be superior to the current methods that they are
compared to here in the scenarios presented. It would be useful to implement a large
scale repetitive simulation study on BAGS and MVBAGS. In implementing a larger scale
simulation study a wider range of scenarios could be studied and the consistency of the
models could be highlighted.
BAGS and MVBAGS are advantageous not only in their performance at identifying
active gene sets in this simulation study. Rather than a p-value against some null hypoth-
esis with some arbitrarily defined cut-off, we produce Bayesian posterior probabilities.
These probabilities allow us to assess the ‘interestingness’ of a gene set and to express
our uncertainty of this gene set being active, rather than to say ‘yes this gene set is related
to phenotype’ or ‘no this gene set is not related to phenotype’.
The advantage of using such modelling techniques as part of a Bayesian model is
that we can easily access behind the scenes. For example if we have a gene set where
P[active] = 0.5 we can quickly and easily look at histograms to determine which genes
within the set are having an affect on phenotype and asses trace plots of individual param-
eters for convergence issues. In a real life situation when we have borderline cases such
as in the example above, simply looking at trace plots of individual genes would give a
good indication whether to pursue investigation into the gene set or not.
Another advantage is that once an active set has been identified, posterior samples for
the gene effect parameters within the gene set can be accessed and we also already have
a model that relates the gene set to phenotype.
In conclusion, from the results gained here, it would be recommend to use either
BAGS or MVBAGS over the other methods studied in this thesis.
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Chapter 7
p53 Data set
7.1 Introduction and Background
The two models introduced in Chapter 5 have been shown to work very well when ap-
plied to simulated data in Chapter 6, however there is the need to apply the models to
real data. There are several suitable, freely available datasets at http://www.broadin
stitute.org/gsea/datasets.jsp, for, example there are data on diabetes, leukemia,
lung cancer and p53 mutation status amongst others.
The p53 data is somewhat of a benchmark dataset when proposing new gene set anal-
ysis methodology with analyses presented in the publications of GSEA, GSA and BGSA.
For this reason it has been chosen to apply the first of the two models from Chapter 5 to
the p53 data. The second model will not be applied to the data as further work is required
in programming the model before it can be applied to data where gene sets overlap. This
will be discussed further in Chapter 8.
p53 is a gene that codes for proteins that regulate cell cycle and hence functions as
a tumor suppressor. Damage to DNA and other stress signals from the cell, for example
ionizing radiation, abnormal growth signals from oncogenes, hypoxic stress, the reaction
to hot- or cold-shock and inflammation in tissues can prompt the increase in p53 proteins.
These p53 proteins have three major functions:
• Growth arrest - Stops the progression of the cell cycle, thus preventing the replica-
tion of damaged DNA;
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• DNA repair - During growth arrest p53 may activate the transcription of proteins
involved in DNA repair;
• Apoptosis (cell death) - the ‘last resort’ to avoid proliferation of cells containing
abnormal DNA.
The different types of stress that are responded to by the p53 protein have one thing in
common: they all have the potential to disrupt the efficient and authentic replication of
the cell, resulting in an enhanced mutation rate or aneuploidy during cell division.
Figure 7.1: Simplified p53 activity.
The cellular concentration of p53 must
be tightly regulated. While it can suppress
tumors, high levels of p53 may acceler-
ate the aging process by excessive apopto-
sis. The major regulator of p53 is Mdm2,
which can trigger the degradation of p53
by the ubiquitin system. Figure 7.1 shows
normal p53 activity pictorially. It is ac-
knowledged that in many cancerous tu-
mors the p53 gene can be found to be mu-
tated, and hence not performing its job of
tumor-suppressing. In fact over half of all tumors can be seen to have mutated p53 genes.
It is therefore of great interest to determine pathways related to the mutation of the p53
gene.
As mentioned above the p53 dataset has become something of a benchmark when
proposing new gene set analysis methodology, with analyses presented by Subramanian
et al. (2005), Efron and Tibshirani (2006) and Shahbaba et al. (2011) in the publications of
GSEA, GSA and BGSA respectively. The aim of these analyses was to identify pathways
that are differentially expressed between cell lines with normal and mutated p53 genes.
The same group of gene sets were used by each group, these being the C1 and C2 gene set
catalogues, both freely available at http://w ww.broadinstitute.org/gsea/msigdb/
index.jsp. By combining the C1 and C2 gene set catalogues genes were resultantly al-
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located to 522 overlapping gene sets.
In analyzing the p53 data using the same 522 gene sets, all three groups (Subramanian
et al. (2005), Efron and Tibshirani (2006) and Shahbaba et al. (2011)) found positive
results relating gene sets to p53 mutation status. There are some gene sets that all three
methods agree are related to p53 mutation status and perhaps more interestingly some
gene sets over which the methods disagree. These results will be discussed and compared
later in the chapter.
The rest of the chapter is as follows; Section 7.2 outlines the p53 dataset in detail and
further discusses the allocation of genes to gene sets. Section 7.3 discusses model fitting.
Section 7.4 presents results from applying the first of the two models from Chapter 5
to the p53 data, Section 7.5 compares these results to those presented by Subramanian
et al. (2005), Efron and Tibshirani (2006) and Shahbaba et al. (2011). Finally Section 7.6
discusses results produced and comparisons made between the four methods.
7.2 Data
Original data were obtained on interrogating the mutation status of p53 in cancer cell
lines from the NCI-60 (National Cancer Institute-60) collection (Ross et al. (2000)) which
was created to explore gene expression over 60 subjects diagnosed with various can-
cers. Data from 50 of these cell lines are freely available at http://www.broadinsti
tute.org/gsea/datasets.jsp whereby the expression of 4486 genes is measured over
50 cancer cell lines, 33 of the cell lines having a p53 mutation and the remaining 17 being
wild type.
Min. 1st Qu. Median 3rd Qu. Max.
2.00 10.00 17.00 28.00 358.00
Table 7.1: Summaries of the sizes of the 522 gene sets.
Genes are allocated into 522 gene sets, derived from the C1 and C2 gene set cata-
logues as mentioned previously. The C1 gene set catalogue, known as the positional gene
set collection, is a collection of gene sets corresponding to each human chromosome and
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each cytogenetic band that has at least one gene. These gene sets are useful for identi-
fying effects related to chromosomal amplifications or deletions, dosage compensation,
epigenetic silencing, and other locational effects. The C2 gene set catalogue, known as
the curated gene set collection, consists of gene sets collected from sources such as online
pathway databases, publications in PubMed, and knowledge of experts in the area. In
combining the C1 and C2 gene set catalogues, 522 gene sets were used in each analysis.
No repetitions Frequency
1 1734
2 961
3 573
4 338
5 260
6-10 410
11-20 157
21-40 45
>40 17
Total 15059
Table 7.2: Summary of the number of repetitions of the 4486 genes in the 522 gene sets.
Table 7.1 shows summary statistics of the sizes of these gene sets. As can be seen
gene set sizes are generally spread about 17, however there are some gene sets containing
very few genes and some gene sets containing very large numbers of genes. It can be seen
from the five number summary in Table 7.1 that the distribution of gene set sizes is very
positively skewed. The majority of these gene sets are overlapping, in particular some of
the larger gene sets consist almost entirely of smaller gene sets.
Table 7.2 shows a frequency table of the number of times genes have been represented
within the 522 gene sets. As can be seen many genes are represented several times, for
example the gene known as NFKB1 (NF-kappa-B) is represented 51 times in the 522 gene
sets. NF-kappa-B is a gene which influences multiple phenotypic traits, it is present in
almost all cell types and is involved in many biological processes such as inflammation,
immunity, differentiation, cell growth, tumorigenesis and apoptosis. It would therefore be
expected that such a gene would appear many times.
The goal is to identify pathways that are differentially expressed between cell lines
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with mutated and normal p53 genes.
7.3 Model fitting
There are several sets of parameters that must be provided in order to fit the model. Before
defining these parameters it is useful to refresh the definition of the model. As mentioned
in Chapter 5, two logistic models are defined, both models having the same likelihood.
Looking within gene set s, containing ms genes, the likelihood is given by
f (x|β ) =
n
∏
i=1
piyii (1−pii)1−yi (7.1)
where
pii =
1
1+ exp{−ηi} (7.2)
and
ηi = xiβ (7.3)
where xi is the vector of ms gene expressions corresponding to gene set s in the ith subject
and β is the vector of slope parameters for gene set s.
The null and active models are distinguished by their respective prior distributions.
The prior for the null model (M1) is given by
f (β ) =
1√
2piσ
exp
{
−β 2
2σ2
}
(7.4)
and the prior for the active model (M2) is given by
f (β )=
1√
2pi
(
(1− p)
2σ1
exp
{−(β −µ)2
2σ21
}
+
p
σ2
exp
{
−β 2
2σ22
}
+
(1− p)
2σ1
exp
{−(β +µ)2
2σ21
})
(7.5)
The prior information for the model move is specified to represent the belief that relatively
few gene sets will have an effect on phenotype. The prior information for the active model
is specified to represent beliefs that relatively few genes within an active gene set will have
a large (either positive or negative) effect upon phenotype, whilst most of the genes will
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have little effect on phenotype. The prior distribution for the null model is specified to
represent the belief that within an inactive gene set gene effects will be small and centered
about zero. We therefore define the prior parameters as follows:
1 Null model prior parameters:
• σ = 0.1
2 Active model prior parameters:
• σ1 = 0.05
• σ2 = 0.6
• µ = 1
• p = 0.8
3 Reversible jump prior:
• P[M2] = 0.8
We put these models in a RJMCMC framework, whereby not only do we propose new
parameters (β ) for a model and accept with probability α(β ,β prop) but we also propose
to move from the null model (M1) to the active model (M2) with probability α(M1,M2)
and vice versa.
The within model proposal distribution, which is used in Algorithm 4.1, is given by
q(βprop|β ) = 12(1−q)N(−δ ,τ
2
1 )+qN(β ,τ
2
2 )+
1
2
(1−q)N(δ ,τ21 ) 0 < q < 1 (7.6)
The parameters for the within model proposal distribution have been chosen to speed up
convergence of chains, based on the experimentation presented in Chapter 4. These are:
• τ1 = 0.05
• τ2 = 0.6
• δ = 2
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• q = 0.8
Chapter 5 also describes the necessity for a mixing aid within the reversible jump
move of the model. This mixing aid is simply the addition of a zero mean random variable
to the parameters when moving from one model to the other. We define this as
β ′ = β +N(0,σ2mix) (7.7)
On running the algorithm and systematically exploring values for σmix it is found that the
best σmix = 0.0675.
The model is applied to the p53 dataset with Markov chain Monte Carlo simulations
for 50,000 iterations, of which the first 20,000 are discarded as burn-in. Convergence has
been assessed by checking trace plots. Due to the number of parameters the full set of
trace plots are not provided. However, Figure 7.2 shows two typical trace plots obtained.
Figure 7.2 panel A shows a trace plot for the model moves for a randomly selected gene
set, this being parkinsonsPathway. Figure 7.2 panel B shows a trace plot of the posterior
samples for the parameter of a gene in this set, this being PARK. As can be seen in both
cases chains mix well. The chain for the model move explores the space of models well,
with moves to both models accepted frequently. The chain for the gene parameter can be
seen to converge about zero.
7.4 Results
Figure 7.3 shows a plot of the density of the posterior probabilities of activeness for the
522 gene sets. A distinct separation between active and in-active gene sets can be seen
in the bi-modality of the posterior distribution. This shows the ability of the model to
distinguish between active and inactive sets.
Figure 7.4 shows a plot of the density of 1-(p-value) from the BGSA of the 522 gene
sets. These are the results reported by Shahbaba et al. (2011) and were obtained from
http://www.ics.uci.edu/ babaks/Site/Home.html. This plot gives a very differ-
ent picture from that produced by the proposed model. Here can be seen a roughly bell
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Panel A: Trace plot of model moves for gene set parkinsonsPathway
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Figure 7.2: Panel A shows trace plot of model moves for gene set parkinsonsPathway with
P[active] = 0.03347. Panel B shows a trace plot of the posterior samples for the pa-
rameter corresponding to PARK gene within this gene set.
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Figure 7.3: Plot showing posterior distribution of P[active]
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shaped curve with a mode at approximately 0.5. There can be seen no separation between
active and in-active gene sets, instead we see the curve flattening off in either extreme. The
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Density plot of 1−pvalue for BGSA
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Figure 7.4: Plot showing posterior distribution of 1− (p− value) for BGSA
p-values other than those in the right hand tail of the plot in Figure 7.4 tell us little. How-
ever, in comparison all probabilities shown in Figure 7.3 have a clear and interpretable
meaning:
• Those in the mode at zero tell us that these corresponding gene sets are very unlikely
to have a relationship with p53 mutation status;
• The relatively few probabilities between this mode and 0.5 tells us that these gene
sets are unlikely to have a relationship with p53 mutation status;
• The probabilities between 0.5 and the right hand mode tell us that the corresponding
gene sets could have a relationship with p53 mutation and the further to the right
we go the more worthy these gene sets are of further investigation;
• The probabilities that make up the mode near 1 indicate that the corresponding gene
sets are very likely to have a relationship with p53 mutation status and investigation
and interpretation would certainly be worthwhile.
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Figure 7.4 also highlights the problem of arbitrarily setting a p-value cut off. A cut off
of p ≤ 0.1 is recommended in Shahbaba et al. (2011), this translates to (1− p) ≥ 0.9 in
the plot in Figure 7.4. It could be that all gene sets not contained in the central mode are
interesting and in setting this cut off we discard more than half of them. Conversely, we
see a clear group of interesting gene sets from the plot in Figure 7.3, there is no cut off
on the probabilities and so none of these potentially interesting and active gene sets are
overlooked.
From a practical point of view the results shown in Figure 7.3 would be much better
to deal with than those shown in Figure 7.4. This is because the proposed model not only
clearly distinguishes the active gene sets from all others but also provides probabilities of
activeness, thus making all results meaningful and interpretable.
Figure 7.5 shows all positive results gained from applying the first of the two models
from Chapter 5 to the p53 data, where a positive result is defined as P[active] ≥ 0.5.
Clearly we would not class all of these gene sets as particularly influential on p53 mutation
status, however, it is of interest to identify all gene sets with some positive result.
Of greater interest are the gene sets where the probability of activeness is very high.
Table 7.3 shows gene sets where P[active] ≥ 0.95, of which there are 22. Of these 22
gene sets, many are large gene sets, with 12 out of the 22 gene sets containing more than
100 genes. There can be seen to be three main themes to the gene sets that are found to
be active. These are:
1 Cell cycle, cell growth and cell death - Associated with tumor growth and suppres-
sion, which is governed by p53;
2 Hypoxia and respiratory system - Hypoxic stress, like DNA damage, induces the
accumulation of p53 proteins;
3 Energy production and transportation - p53 mediates metabolic changes in cells
through the regulation of energy metabolism and oxidative stress.
These three themes are interconnecting and extremely complex. These themes are well
documented in their relationships with p53, for example Vogelstein et al. (2000), Harris
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and Levine (2005) and Puzio-Kuter (2011).
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Figure 7.5: Plot showing probabilities for gene sets with P[active]≥ 0.5 on a logit scale
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7.5 Comparisons with GSEA, GSA and BGSA
Table 7.4 shows published results from Subramanian et al. (2005), Efron and Tibshirani
(2006) and Shahbaba et al. (2011) from analyses of the p53 data using GSEA, GSA and
BGSA respectively. Table 7.4 also shows the results gained from the analysis presented
in this chapter, along with relevant gene set sizes. Also, three of the most probable gene
sets identified by BAGS, but none of the other methods, are shown.
Pathway Gene set size GSEA maxmean BGSA BAGS
p53hypoxia Pathway 20 < 0.0001 significant 0.011 0.9858
hsp27 Pathway 15 < 0.0001 significant . . . 0.3101
p53 Pathway 16 < 0.0001 significant 0.004 0.9937
P53 UP 40 0.0013 significant 0.016 0.8039
radiation sensitivity 26 0.0078 significant 0.004 0.8125
ras Pathway 22 0.1710 significant . . . 0.2015
SA G1 AND S PHASES 14 . . . significant . . . 0.9820
DNA DAMAGE SIGNALLING 90 . . . . . . 0.047 0.9453
cell cycle regulator 23 . . . . . . 0.023 0.7637
n.g.f pathway 19 . . . significant . . . 0.0667
ATM pathway 19 . . . . . . 0.079 0.9800
g2 pathway 23 . . . . . . 0.091 0.7275
BAD pathway 21 . . . . . . 0.098 0.9809
p53signalling 87 . . . . . . . . . 0.9955
CR protien mod 146 . . . . . . . . . 0.9940
human mito db 326 . . . . . . . . . 0.9926
Table 7.4: Table showing q-values from GSEA with an FDR cut off of 0.25, indication of signif-
icant gene sets from GSA (with an FDR cut off of 0.1), p-values for BGSA with a cut
off of 0.1 and P[active] for BAGS. All cut offs are defined in the relevant publication of
the methods.
It can be seen that for all gene sets found to be significantly related to p53 mutation
status by BGSA, BAGS attaches high probabilities of activeness. In fact, it is only the SA
G1 AND S PHASES pathway over which the method presented and BGSA disagree.
There are two cases where both GSEA and GSA identify gene sets as significantly
related to p53 mutation status, whilst BGSA does not and BAGS gives low associated
probabilities of activeness. These are the hsp27 pathway and the ras pathway.
GSA identifies SA G1 AND S PHASES as significant, which is in agreement with
BAGS but disagreement with GSEA and BGSA. GSA also identifies the n.g.f pathway as
significant which none of the other methods do.
In general BAGS gives consistent results with those gained by the three other methods.
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There is also strong evidence that several additional gene sets are related to p53 mutation
status as shown in Table 7.3. For example, the gene set given the highest probability
of activeness by BAGS, p53signalling (P[active] = 0.9955) is not identified by the three
existing methods. The reason for this is that of the 87 genes within the gene set there are
only six genes with absolute effects of ≥ 0.5. The three existing methods miss this strong
gene set effect because of their univariate nature. The relatively few gene effects within
the set are diluted by all of the genes with little to no effect. It should be noted that all
gene sets identified by GSEA and GSA are small and only one large gene set is identified
by BGSA. This is due to the dilution of effects within the larger gene sets.
7.6 Discussion
BAGS can be seen to work well on the p53 data set. Several gene sets have been found to
be strongly related to p53 mutation, many of these being previously unidentified by Sub-
ramanian et al. (2005), Efron and Tibshirani (2006) or Shahbaba et al. (2011). Looking at
the biological literature, for example Vogelstein et al. (2000), all of these pathways have
an interpretable connection with p53 mutation status.
Notably in comparison to BGSA (Figures 7.3 and 7.4) the proposed model clearly
separates active and in-active gene sets. Moreover, by providing the posterior probabilities
of activeness, our method does not rely on arbitrarily defined cut-offs unlike the three
other methods studied in this thesis, who all suffer from this serious disadvantage.
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Chapter 8
Discussion and future work
8.1 Summary
Genomewide expression analysis with DNA microarrays have become key in many ge-
nomics research projects over the past decade. The challenge of extracting meaningful
biological insight and determining interpretable and reproducible results from such anal-
yses has become an active area of research in itself. There is much interest in gene set
analyses methods, which are a very popular tool for managing the above problem, with
many researchers aiming to improve interpretation and reproducibility of microarray anal-
yses through the inclusion of additional biological information.
This thesis focuses on methodology which attempts to relate biologically defined sets
of genes with phenotype. A gene set comprises some number of genes that are related
either by location on the chromosome or by function and methodology is based on the
expectation that the effect on phenotype is restricted to a small number of gene sets. A
typical data set upon which these methods would be employed would consist of gene
expression measurements of thousands of genes across any number of subjects (generally
small). Gene expression is typically transformed such that it follows a standard normal
distribution, this transformation is generally relied upon by methodologies in this area.
This thesis begins by reviewing and comparing some of the existing methodology for
the analysis of sets of genes. There are many methods from which to choose, yet here we
focus upon three of the available methods: GSEA, GSA and BGSA. GSEA brought gene
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set analysis methods to the forefront and was chosen as it is the most widely cited gene
set analysis method to date. One such paper citing GSEA is that by Efron and Tibshirani
(2006), who generalize the GSEA framework and introduce a new methodology for the
analysis of gene sets that is developed under this general framework, coined GSA. Finally,
BGSA was chosen for two reasons, firstly as it represents the latest methodology; first
published in 2011. Secondly BGSA was chosen as it is one of the few available Bayesian
methodologies for the analysis of gene sets.
Chapter 2 describes these methods in detail, discusses the papers presenting them, and
critically looks at the methods from a modelling perspective. A defining characteristic of
these methods is that they are based on a construction in which the dependency between
gene expression and outcome is defined in terms of the conditional distribution of gene
expression|phenotype. One consequence of this, covered in Chapter 3, is that in published
simulation studies where data are simulated assuming such a relationship expression lev-
els for active genes no longer follow a standard normal distribution, thus removing any
standardization. From both a biological and a statistical modelling perspective it could
be interesting to model phenotype conditionally on gene expression. This way of condi-
tioning would give much more justification to the term ‘pathway to phenotype’. Gene set
analysis is based on the notion that a small minority of genes restricted to a small num-
ber of gene sets are substantially associated with phenotype but others have little or no
association with phenotype. This notion can be captured formally in the prior distribution
of a Bayesian analysis. Many of the remarks made in Chapter 2 about GSEA, GSA and
BGSA are true for the majority of work in the area of gene set analysis methodologies.
Chapter 3 proceeds to study the behavior of these methods by way of an extensive
simulation study. This chapter begins by focusing upon data simulation, in particular the
conditionality between phenotype and gene expression when simulating data. A new data
simulation procedure is introduced, whereby phenotype is simulated conditional on gene
expression, the reverse of the general assumption of modelling expression|phenotype.
This simulation procedure maintains the standard normal marginal distribution whilst al-
lowing for associations between phenotype and gene expressions. This is an improve-
154
ment over the generally accepted data simulation procedure, where for active genes data
are simulated in such a way that removes the standardization. This new data simulation
procedure also allows for the definition of a correlation structure.
All three of the methods can be seen to work well in some scenarios. However, when
there are both up- and down-regulated genes within a gene set the performance of GSA
and particularly GSEA suffers. It is also shown that as pairwise correlation between
genes within gene set increases, the performance of all three methods drops. This can
be attributed to increased numbers of false positive results with correlated data, which in
turn is caused by the conditioning of the three methods. Finally, it is discussed that the
necessity of a p-value cut-off to determine a gene set active/inactive can be somewhat
restrictive when interpreting results.
The exploratory nature of these chapters allowed us to reflect upon possible improve-
ments and areas of development for the models as proposed in this thesis. Chapters 4 to 6
focus upon methodology based on the following principles:
• Rationale: Rather than using ad-hoc analytical methods to determine differential
expression, probability models should be used to represent biological mechanisms;
• Conditioning: Condition phenotype on gene expression rather than gene expression
on phenotype;
• Model formulation: Use multivariate models rather than large scale univariate test-
ing or modelling;
• Prior Information: The notion that a small minority of genes, restricted to a small
number of gene sets are substantially associated with phenotype, whilst others have
little or no association with phenotype, should be reflected in a prior model.
• Output: Produce posterior probabilities of activeness of gene set rather than a p-
value with a corresponding arbitrarily defined cut-off.
In this thesis models in which phenotype is assumed conditional on gene expression
have been explored. The comparison between such models and the existing methods is
analogous to the comparisons between a series of t-tests and a logistic regression.
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The models as introduced in Chapters 4 and 5 rely upon the definition of strong prior
distributions. The model for an active gene set makes use of a strong prior for gene effects
based on a mixture of three normal distributions. The motivation for such a prior was that
we know there will be a range of gene effects: those with no effect upon phenotype, those
with a relatively large positive effect on phenotype and finally those with a relatively large
negative effect on phenotype. The model for an inactive (null) set uses a strong prior based
on a normal distribution with mean zero and a small variance to represent beliefs that gene
effects within a null gene set will be small and centered about zero.
Chapter 4 proposes a hybrid Bayesian/ frequentist model that employed the above
points, except for producing a posterior probability of activeness. The problem of taking
the information from a group of genes and reducing this into a probability proved to be
problematic and therefore a frequentist style p-value was calculated thus rendering this a
hybrid approach. Most importantly, Chapter 4 proposed Bayesian models for gene sets
and introduced and calibrated an MCMC algorithm to obtain posterior samples of the
parameters of these models, which gave a good base from which to design fully Bayesian
approaches.
The null and active gene set models as introduced in Chapter 4 proved to fit simu-
lated data well, however, the gap between fitting these models and producing a posterior
probability of activeness needed to be bridged. In implementing a more general RJM-
CMC algorithm that allowed the previous MCMC algorithm to jump between the null
and active models, posterior probabilities for activeness could be produced. Chapter 5
introduces and describes this model (BAGS) in detail. In fitting this model, some mix-
ing problems were encountered in the reversible jump step. These mixing problems were
overcome by the addition of a zero mean random variable in the between model variable
transformation stage. Chapter 6 shows that this method works very well when applied to
simulated data, and performs better than the existing methods.
One criticism that could be made of BAGS is that it considers gene sets as independent
and therefore it is not a fully multivariate model. MVBGSA builds upon BAGS and
overcomes this. A fully multivariate approach is proposed whereby all genes and therefore
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gene sets are simultaneously considered. This allows the full correlation structure of the
data set to be accounted for. RJMCMC techniques are again employed to allow for the
exclusion or inclusion of gene sets. This results in a final model where:
• Only gene sets that have an effect on phenotype are included;
• An associated probability for the model formulation is produced;
• Probabilities relating to every gene set’s activeness in the pathway to phenotype are
produced.
MVBAGS therefore not only does the job of a gene set analysis in determining an inter-
esting subset of gene sets, but it also negates the necessity for the typical further analysis
and/or modelling of this interesting subset of gene sets.
Chapter 6 applies and compares GSEA, GSA, BGSA, BAGS and MVBAGS. Exten-
sive, repetitive simulations (as in Chapter 3) were not feasible within the constraints of
this project due to the high computational cost of repeatedly running the models as pro-
posed in Chapter 5. It is discussed how the computational cost of the models should not
be considered detrimental to their practical applicability, due to the availability of rela-
tively powerful machines to the typical user of such methods. The important point to take
from Chapter 6 is that both of the models work very well in all scenarios and that their
performance is superior to the three existing methods.
Chapter 7 presents the application of the first of the two models introduced in Chapter
5 to the p53 data set. We find strong evidence that 22 out of 522 gene sets are strongly
related to p53 mutation status (For each of these gene sets P[active] ≥ 0.95). These 22
gene sets act under one of three themes, these being:
1 Cell cycle, cell growth and cell death;
2 Hypoxia and respiratory system;
3 Mitochondrial function, energy production and energy transportation.
These themes are well documented in their relationships with p53, for example Vogelstein
et al. (2000), Harris and Levine (2005) and Puzio-Kuter (2011). The results obtained in
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Chapter 7 were also compared to the positive results presented by Subramanian et al.
(2005), Efron and Tibshirani (2006) and Shahbaba et al. (2011). It is shown that amongst
the 22 top hitting gene sets, the proposed method identifies the majority of the positive
results found by GSEA, GSA and BGSA. In particular, the most probable two gene sets
identified by BAGS (p53signalling and CR PROTIENMOD ) are not identified by GSEA,
GSA or BGSA. It should also be noted that none of these three methods identify gene sets
related to theme 3 (above).
We do not apply the second of the models from Chapter 5 to the p53 data, as further
work to the programming of this model is required before it can be applied to overlapping
gene sets. This will be discussed in further detail below.
8.2 Future work and further development
In this thesis the problem of analyzing the relationship between the expression of pre-
defined, functionally related sets of genes and phenotype has been investigated. The
models as presented in Chapter 5 can be seen to work well when applied to simulated
data in Chapter 6 and when applied to real data in Chapter 7. The models prove to have
many desirable properties and consistently exhibit superior performance over the existing
methods.
There are many areas where further work is needed and it should be recognised that
this thesis is a starting point for much further research in the area. The following goes on
to discuss some of the possible future work that is beyond the scope of this thesis.
8.2.1 Computational aspects
The next steps in the development of the new models is to make them available in routine
practice by improved implementation within a more efficient computing environment,
such as C++, Fortran or Python. One such future direction for improving the computa-
tional efficiency of these models would be to re-program each model in parallel, such that
when implemented on a multicore processor the job would be split between the available
cores on the machine.
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8.2.2 Simulation and application
The models presented in Chapter 5 are shown to be superior to the existing methods on
the eight simulated data sets in Chapter 6. However, it needs to be shown whether the
methods work consistently rather than in single instances. The models should also be
shown to work across a broader range of scenarios than those presented in Chapter 6. A
future simulation study should systematically vary
• the number of active genes within a gene set.
• gene effect size and direction.
• the number of active gene sets.
• pairwise correlation between genes.
We must be able to identify trends to how the models behave and when and where the
models work well.
The second of the models presented in Chapter 5 needs further development before
it can be applied to real data. It is for this reason that an application to real data is not
provided in Chapter 7. In order to facilitate an application to real data the programs for
the model should be modified to allow for overlapping gene sets.
Consider two gene sets, s = 1 and s = 2 each containing some number of different
genes, but both containing gene g. Now, we cannot allow for two parameters for gene g,
yet if we have a single parameter for gene g then when inevitably we want to remove one
of the sets from the model, but keep the other, there is the question of how to deal with
gene g. A way in which to avoid this problem is to have indicator terms for genes that are
in several sets. In the above example the term for gene g in the likelihood would be
(I(∃s : s = 1)+ I(∃s : s = 2))βgxg
where I() is the indicator function such that I(∃s : s = 1) = 1 if set s = 1 exists in the
model and I(∃s : s= 1) = 0 if set s= 1 does not exist in the model and so on for any other
number of gene sets.
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8.2.3 Modelling
The methodology for the two models introduced in Chapter 5 can be considered as a
starting point for the two models and there are still many areas which need to be further
investigated or in which they could be improved.
Both of the models rely heavily upon the definition of strong prior distributions. How-
ever, little formal investigation has been made into different prior distributions. There are
infinately many distributions that could work for both the active and null models. For
example an alternate prior distribution for the active model could be
f (β ) = pU(−0.1,0.1)+(1− p)U(−2,2)
and an alternate prior for the null model could be
f (β ) =U(−0.2,0.2)
A thorough investigation into the prior distributions for the two models should be carried
out. There are many ways in which we could alter the prior distributions for the first of
two reversible jump models. For example we could relax the prior for the null model
allowing for some active genes within the null model and strengthen the active model,
allowing for fewer non-active genes within an active gene set. Clearly there are infinite
possibilities for such an investigation, but it would be very useful to investigate some
general properties of altering the prior distribution.
In strengthening the prior and allowing for fewer inactive genes within gene set for the
second of the two reversible jump models we would widen the gap between the probability
of inclusion/ exclusion of a gene set. This would increase the number of moves between
models. It would be of interest to see how this might affect the posterior probabilities of
activeness for gene sets.
For the second of the two presented models, it may be interesting to look at adapt-
ing the active model into a hierarchical model, whereby we could put hyperpriors on the
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means, variances and mixing proportions. Possibly this would involve changing the origi-
nal prior to perhaps a bi-modal distribution representing a high proportion of active genes.
Another interesting variation on the second model from Chapter 5 would be to move away
from the idea of gene sets and go through the exclude/ include procedure by gene rather
than gene set.
Covariates such as lifestyle and demographic factors that might be related to pheno-
type or can explain differential gene expression could, with little difficulty, be incorpo-
rated into the gene set analysis models as presented in Chapter 5. For example when
exploring disease phenotypes age, BMI, smoking status, etc could be included into these
models. There is no obvious way of achieving this when the conditioning is done on the
phenotype.
8.2.4 The application of Bayesian networks to gene set analysis
Bayesian networks (BNs) could be applied to the identification of relationships between
pre-defined functionally related sets of genes and phenotype.
A BN is a probabilistic graphical model that represents a set of random variables and
their conditional dependencies via a directed acyclic graph (DAG). Formally, Bayesian
networks are DAGs whose nodes represent random variables and edges represent condi-
tional dependencies. Nodes which are not connected represent variables which are con-
ditionally independent of each other. Each node is associated with a probability function
that takes a particular set of values for the node’s parent variables as input and gives the
probability of the variable represented by the node.
BNs capture linear and non-linear interactions, handle stochastic events accounting
for noise and focus upon local interactions, which can be related to causal inference. BNs
are able to focus on local interactions, where each node is directly affected by a relatively
small number of nodes. Such properties are widely observed in biological networks.
This makes BNs great tools for modelling gene expression data and particularly pathway
analysis.
There are several proposed methods utilizing BNs for gene set analysis. For exam-
ple Isci et al. (2011) use pathway information to model each biological pathway as a BN
161
and quantify the degree to which observed experimental data fit this BN using Bayesian
Dirichlet equivalent (BDe) score calculation. They assess statistical significance for the
BDe score of each pathway by testing it against datasets generated by applying random-
ization via bootstrapping. Some other examples of the use of BN’s for pathway analysis
can be seen in Bauer et al. (2010) and Zou and Conzen (2005) .
There are many ways in which BNs could be used in the context of gene set analysis.
One such approach that follows on from the models presented in this thesis would be to
allow for variable dimension BNs that could either be fully driven by the data, or begin
as pre-defined gene sets. We could allow for the inclusion and exclusion of entire sets of
genes and compute probabilities for relationships between gene sets and phenotype in this
way. A further extension could be to allow for the inclusion and exclusion of genes from
gene sets, such that the pre-defined pathways are used to represent our prior knowledge.
It would also be interesting to look at BN’s driven solely by data to see how (if at all) any
pre-defined pathways are captured and their functional relationship(s) with phenotype.
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Appendix A
Appendix
A.1 Single Componenent updating with Independence sam-
pler
Parameter G-R Point est. G-R Upper C.I. Acceptance rate
β1 1.0007 1.0017 0.1203
β2 1.0017 1.0038 0.1166
β3 1.0036 1.0051 0.0493
β4 1.0096 1.0111 0.0458
β5 1.0071 1.0085 0.0584
β6 1.0034 1.0046 0.0515
β7 1.0067 1.0090 0.0493
β8 1.0070 1.0084 0.0535
β9 1.0063 1.0109 0.0485
β10 1.0022 1.0040 0.0616
Table A.1: Point estimates of potential scale reduction factor, corresponding upper confidence lim-
its and acceptance rates for the ten logistic slope parameters
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A.2 Single component updating random walk
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Parameter G-R Point est. G-R Upper C.I. Acceptance rate
β1 1.0057 1.0120 0.5258
β2 1.0144 1.0347 0.5197
β3 1.0857 1.1353 0.3678
β4 1.0203 1.0319 0.3663
β5 1.0867 1.1518 0.3810
β6 1.0494 1.0767 0.3740
β7 1.0875 1.1607 0.3726
β8 1.0166 1.0272 0.3722
β9 1.0156 1.0221 0.3711
β10 1.0468 1.0981 0.3808
Table A.2: Point estimates of potential scale reduction factor, corresponding upper confidence lim-
its and acceptance rates for the ten logistic slope parameters.
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A.3 Single component updating with bi-modal indepen-
dence sampler
Parameter G-R Point est. G-R Upper C.I. Acceptance rate
β1 1.0025 1.0037 0.0227
β2 1.0143 1.0354 0.0221
β3 1.0016 1.0023 0.4829
β4 1.0004 1.0006 0.4795
β5 1.0000 1.0001 0.4702
β6 1.0028 1.0034 0.4877
β7 1.0027 1.0042 0.4707
β8 1.0010 1.0018 0.4707
β9 1.0008 1.0011 0.4816
β10 1.0010 1.0016 0.4419
Table A.3: Point estimates of potential scale reduction factor, corresponding upper confidence lim-
its and acceptance rates for the ten logistic slope parameters.
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A.4 Single component updating with tri-modal indepen-
dence sampler
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Parameter G-R Point est. G-R Upper C.I. Acceptance rate
β1 1.0086 1.0212 0.0451
β2 1.0057 1.0137 0.0422
β3 1.0006 1.0009 0.2214
β4 1.0017 1.0018 0.2279
β5 1.0060 1.0088 0.2184
β6 1.0013 1.0015 0.2253
β7 1.0016 1.0024 0.2143
β8 1.0035 1.0048 0.2145
β9 1.0040 1.0046 0.2249
β10 1.0008 1.0017 0.2090
Table A.4: Point estimates of potential scale reduction factor, corresponding upper confidence lim-
its and acceptance rates for the ten logistic slope parameters.
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A.5 Single component updating with tri-modal random
walk sampler
Parameter G-R Point est. G-R Upper C.I. Acceptance rate
β1 1.0168 1.0433 0.5805
β2 1.0397 1.0915 0.2839
β3 1.0138 1.0253 0.4103
β4 1.0483 1.0623 0.4131
β5 1.0919 1.2133 0.4296
β6 1.1573 1.2884 0.4088
β7 1.0662 1.1006 0.4119
β8 1.0986 1.1971 0.4231
β9 1.0711 1.1205 0.4139
β10 1.0214 1.0340 0.4066
Table A.5: Point estimates of potential scale reduction factor, corresponding upper confidence lim-
its and acceptance rates for the ten logistic slope parameters.
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A.6 Block updating with random walk sampler
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Parameter G-R Point est. G-R Upper C.I.
β1 1.0062 1.0161
β2 1.0038 1.0104
β3 1.0054 1.0100
β4 1.0029 1.0077
β5 1.0051 1.0120
β6 1.0085 1.0198
β7 1.0155 1.0369
β8 1.0343 1.0862
β9 1.0016 1.0024
β10 1.0029 1.0069
Table A.6: Point estimates of potential scale reduction factor, corresponding upper confidence lim-
its and acceptance rates for the ten logistic slope parameters.
beta 1
Time
0 2000 4000 6000 8000 10000
0.
7
0.
8
0.
9
1.
0
1.
1
1.
2
1.
3
1.
4
221
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 1
beta 2
Time
0 2000 4000 6000 8000 10000
−
1.
4
−
1.
3
−
1.
2
−
1.
1
−
1.
0
−
0.
9
−
0.
8
222
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 2
beta 3
Time
0 2000 4000 6000 8000 10000
−
0.
25
−
0.
20
−
0.
15
−
0.
10
−
0.
05
0.
00
0.
05
0.
10
223
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 3
beta 4
Time
0 2000 4000 6000 8000 10000
−
0.
10
−
0.
05
0.
00
0.
05
0.
10
0.
15
224
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 4
beta 5
Time
0 2000 4000 6000 8000 10000
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
225
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 5
beta 6
Time
0 2000 4000 6000 8000 10000
−
0.
5
−
0.
4
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
226
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 6
beta 7
Time
0 2000 4000 6000 8000 10000
−
0.
4
−
0.
3
−
0.
2
−
0.
1
0.
0
227
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 7
beta 8
Time
0 2000 4000 6000 8000 10000
0.
0
0.
1
0.
2
0.
3
0.
4
228
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 8
beta 9
Time
0 2000 4000 6000 8000 10000
−
0.
2
−
0.
1
0.
0
0.
1
229
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 9
beta 10
Time
0 2000 4000 6000 8000 10000
−
0.
6
−
0.
5
−
0.
4
−
0.
3
−
0.
2
−
0.
1
0.
0
230
0 20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
AC
F
beta 10
0 5000 10000 15000 20000
0
50
10
0
20
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 5000 10000 15000 20000
0
50
15
0
25
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 5000 10000 15000 20000
0
50
10
0
15
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 5000 10000 15000 20000
0
50
15
0
25
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 5000 10000 15000 20000
0
10
0
30
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 5000 10000 15000 20000
0
50
15
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
231
0 5000 10000 15000 20000
0
10
0
30
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 5000 10000 15000 20000
0
50
15
0
25
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 5000 10000 15000 20000
0
50
15
0
25
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 5000 10000 15000 20000
0
50
15
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
A.7 Block updating with tri-modal random walk sam-
pler
Parameter G-R Point est. G-R Upper C.I.
β1 1.0265 1.0676
β2 1.0175 1.0444
β3 1.0245 1.0408
β4 1.0022 1.0053
β5 1.0219 1.0552
β6 1.0332 1.0746
β7 1.0292 1.0667
β8 1.0379 1.0922
β9 1.0204 1.0476
β10 1.0162 1.0380
Table A.7: Point estimates of potential scale reduction factor, corresponding upper confidence lim-
its and acceptance rates for the ten logistic slope parameters.
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Glossary of terms
Epigenetics the study of heritable changes in gene expression or phenotype due to pro-
cesses other than changes in the underlying genetic sequence.
Gene expression The level of protein production from genes.
Gene set A pre-defined group of genes.
Microarray is a collection of microscopic DNA spots attached to a solid surface.
Normalization The process by which raw gene expression data is standardized to mini-
mize experimental error and to indroduce a common scale.
Nucleus A membrane-enclosed organelle found in eukaryotic cells containing most of
the cell’s genetic material.
Organelle A specialized subunit within a cell that has a specific function.
Phenotype The set of observable characteristics of an individual resulting from the in-
teraction of its genotype with the environment.
Transcription The process of creating a complementary RNA copy of a sequence of
DNA.
Translation The process by which messenger RNA (mRNA) is decoded by the ribosome
to produce a specific amino acid chain, or polypeptide, that will later fold into an
active protein.
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